<SEC-DOCUMENT>0001193125-15-137131.txt : 20150420
<SEC-HEADER>0001193125-15-137131.hdr.sgml : 20150420
<ACCEPTANCE-DATETIME>20150420090130
ACCESSION NUMBER:		0001193125-15-137131
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150420
FILED AS OF DATE:		20150420
DATE AS OF CHANGE:		20150420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		15779641

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d911284d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of April, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 20&nbsp;April 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g68q31.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary Shares on issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">281 M</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of
Directors</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman &amp; Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20&nbsp;April
2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CANTRIXIL HIGHLY SUCCESSFUL IN PREVENTING GROWTH OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHEMO-RESISTANT OVARIAN CANCER</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Animal model highly representative of late-stage ovarian cancer in women</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Model proven
resistant to all previous experimental and standard therapies</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Cantrixil providing potent anti-cancer effect.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Philadephia PA (Monday Apr 20, 2015).</B> US-Australian drug discovery company, Novogen
Ltd, (ASX:NRT; NASDAQ:NVGN), its subsidiary, CanTx, Inc, and Yale University today disclosed key pre-clinical data on experimental anti-cancer drug, Cantrixil, justifying the optimism in the ability of this drug candidate to significantly improve
the survival outlook for patients with ovarian cancer. The data was presented by Professor Gil Mor of Yale Medical School to the American Association for Cancer Research (AACR) Annual Meeting.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development of chemo-resistance is a major hurdle in the management of patients with
ovarian cancer and this phenomenon is responsible for the high mortality associated with this disease. Growing evidence suggests that chemo-resistance is due to the presence in the tumor of a population of cancer cells with stem cell-like properties
that are inherently drug-resistant, surviving radiotherapy and chemotherapy to produce a recurrent cancer re-populated with a new generation of chemo-resistant cancer cells.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is an urgent need to develop treatments that will kill this population of stem cell-like cancer cells before they have a chance to establish a high
degree of chemo-resistance. <B>That is the rationale behind the development of Cantrixil, and the current data suggests that Cantrixil has the potential to be such a breakthrough treatment.</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Researchers at the Yale Medical School have established clinically relevant in vitro and
in vivo models of chemo-resistant ovarian cancer, providing a tool that drug developers increasingly are accessing to screen prospective drugs against. This is a highly stringent screen that Yale believes provides a rapid go/no-go decision point for
lead drug-candidates. To date, no drug candidate has provided a meaningful or durable anti-cancer effect in this model<B>. In this highly aggressive model, intra-peritoneal Cantrixil treatment effectively prevented tumor recurrence by 95%.</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In vitro studies have been reported previously. TRXE-002 initially was identified as
having potent activity against epithelial ovarian cancer (EOC) stem cells, inducing cell death (apoptosis) in a library of patient-derived EOC stem cells (IC50 of 130 - 250 nM).</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g31b33.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g80l95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To replicate recurrent ovarian cancer in vivo, Yale researchers inject human ovarian cancer stem cells directly into the
peritoneal cavity of mice where they develop into a highly aggressive cancer that spreads throughout the abdominal cavity. The appearance and behavior of the cancer mirrors human ovarian cancer primary disease. Once established, the mouse then is
treated with the chemotherapy drug, paclitaxel, the standard first-line treatment for ovarian cancer. Following an initial partial response, the tumor quickly regains rapid growth despite ongoing paclitaxel therapy. This produces a late-stage cancer
condition (secondary or recurrent disease) that replicates the situation that Cantrixil will encounter initially in the clinic. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the model of primary
disease, Cantrixil administered intraperitoneally as a monotherapy inhibited tumor growth in a dose-dependent manner, significantly reducing terminal tumor burden by &gt;90% (dosage 100 mg/kg; p&lt;0.01) over 17-days of treatment. The treatment was
well tolerated with no evidence of bone marrow toxicity or local abdominal toxicity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More importantly, Cantrixil performed equally well in the far more
stringent model of recurrent disease. In this model, following an initial 12-day treatment period with paclitaxel, tumors failed to recur (&lt;95% terminal tumor burden) in those animals switched to daily treatment with intra-peritoneal Cantrixil,
compared to animals that remained on treatment with paclitaxel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lead Investigator, Gil Mor MD PhD, said, &#147;This animal data shows that it is possible
with a drug that targets the chemo-resistant ovarian cancer stem cells to prevent recurrence. Taken together, the data from both the primary and recurrent disease models demonstrate that not only is Cantrixil effective as a first-line monotherapy in
a clinically relevant model of ovarian cancer, but more importantly it also prevents tumor recurrence, again in a highly relevant model of drug-resistant and recurrent ovarian cancer,&#148; Mor added. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Brown PhD, Novogen Group Chief Scientific Officer, said, &#147;Gil Mor&#146;s team have shown that cell death from TRXE-002 is associated with the
activation of the pro-death JNK pathway, concurrent with down-regulation of the MAPK pro-survival pathway through prevention of p-ERK signaling. As a molecular biologist, this is a particularly exciting discovery because this novel dual effect on
cell-death and cell-survival pathways is believed to explain why TRXE-002 is such an efficient killer of both ovarian cancer cells and the highly chemo-resistant ovarian cancer stem cells, and opens up the opportunity for an entirely new class of
chemotherapy.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Graham Kelly, Novogen Group Chief Executive Officer, said, &#147;It is easy to downplay the importance of pre-clinical data. But the
significance of this data needs to be seen in the perspective of the high failure rate of anti-cancer drugs that enter the clinic. For every 50 experimental anti-cancer drugs that enter the clinic, only 1 or 2 ever make it to market. There are a
multitude of reasons for this appallingly high attrition rate, but one of the main ones is the lack of relevance of the animal model that was used to justify bringing it into patients in the first place.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The animal models developed by Yale bring an entirely new level of stringency to the quest for finding an effective treatment for both primary and
recurrent ovarian cancer. The performance of Cantrixil in a model that arguably is the most representative of human ovarian cancer yet developed gives us reason to be confident about the potential of this agent as a new form of chemotherapy for this
significant unmet clinical need.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g31b33.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g80l95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ovarian Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 1 in 70 women will develop ovarian cancer in their lifetime. In the US this equates each year to approximately 22,000 new cases diagnosed and
15,000 deaths from ovarian cancer; the figures for Europe are 66,000 and 41,000 respectively. There are different forms of ovarian cancer with epithelial ovarian cancer accounting for 90% of cases. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 15% of women present with disease localized to the ovaries and with successful surgery the 5-year survival rate is &gt;90%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For women with more advanced disease at the time of diagnosis, the 5-year survival rate is &lt;30%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 85% of advanced cases respond to first-line therapy (typically paclitaxel and carboplatin), but 80% of these will relapse within several years.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cantrixil </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil is a cyclodextrin
envelope containing the active ingredient, TRXE-002. The construct has been designed as an intra-cavity chemotherapy to be injected directly into the peritoneal and pleural cavities without causing local irritation or toxicity. Its purpose is to
achieve high drug levels in the environment in which the cancer is spreading through the migration of the cancer stem cells are spreading. The ultimate primary indication of Cantrixil to be sought is first-line therapy of early-stage cancers of the
abdominal cavity (e.g. ovarian, uterine, colo-rectal and gastric carcinomas). Cantrixil will enter the clinic in later-stage cancers where the abdominal carcinomatosis has resulted in the terminal condition of malignant ascites. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil is owned by CanTx, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TRXE-002 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRXE-002 is a small molecule cytotoxic belonging to a family of compounds whose anti-cancer function is based on various biological effects including
inhibition of trans-membrane electron-transfer mechanisms. TRXE-002 is pan anti-cancer acting, resulting in caspase-dependent apoptosis of both stem cell-like cancer cells and their daughter cancer cells. The compound has a high therapeutic index
with little cytotoxic effect on non-tumor cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CanTx, Inc </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CanTx is a joint venture company between Novogen and Yale University. Novogen has licensed the drug candidate, TRXE-002, to CanTx for use in Cantrixil. CanTx
is based in New Haven, CT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ
(&#145;NVGN&#146;). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two main drug technology
platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the cancer stem (tumor-initiating) cell. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM compounds target the micro-filament component of the cancer cell&#146;s cytoskeleton and have been designed to combine with anti-microtubule drugs
(taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g31b33.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g80l95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company pipeline comprises two SBP drug candidates (TRXE-002, TRXE-009) and one ATM drug candidate (<I>Anisina</I>).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on our website <U>www.novogen.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Graham Kelly</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Chairman &amp; CEO</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Graham.Kelly@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4100</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cristyn Humphreys</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cristyn.Humphreys@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472
4111</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934.&nbsp;The Company has tried to identify such forward-looking statements by use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148; &#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of
identifying such statements.&nbsp;Such statements include, but are not limited to any statements relating to the Company&#146;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company&#146;s drug development program, including, but not limited to, </I><I>Cantrixil and TRXE-002</I><I>, and any other statements that are not historical facts.&nbsp;Such statements involve risks and uncertainties, including, but not limited
to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company&#146;s drug components, including, but not limited to </I><I>Cantrixil and
TRXE-002</I><I>, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, </I><I>Cantrixil
and TRXE-002</I><I>, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to
</I><I>Cantrixil and TRXE-002</I><I>, and other&nbsp;risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.&nbsp;Such
statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.&nbsp;Accordingly, you should not
rely on those forward-looking statements as a prediction of actual future results.</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g911284g31b33.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g911284g31b33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g911284g31b33.jpg
M_]C_X03817AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``"OR````G$``*_(```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHP-B`Q,SHU-CHS.0```Z`!
M``,````!``$``*`"``0````!```"RZ`#``0````!````/0`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```.B`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`#@"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`],),G4\J+[65M+['AC!R
MYQ@*1Y/Q5?-]`XY&3(JD21,S^;]#W)*-UHCMZMAL:2VW41!<'!NI_>A#=E7V
MM#FV0TZ@LT!']8(.SI>TEC_"`>>?Y358;MV-V_1C3X?-.T8_6=Z']UKDV_O.
M/]H_WIM[_P!YW^<?[U8/I]X^7^Q0(K_>^]);2-MUS/HV.'S)'XJQCY%]E@8[
M4$'42.$`;>T?+E&PW%UXEI;`/TH\/Y+G)%,;L;MP-?()/XJ<GQ*9)-95Y/B4
MQ)CDI))*8R[Q*!D&0TDD1/<C^*.YSA(#"?,D`?\`?G*IE.K(:,AD"3L+7:_R
MNR(1(Z-:UT/_`$;B!&NTF)4=[_WW?YQ_O1'5XY$LM(\GM/\`U3$(B#$@^8F/
MQA.83:G%SA#G.(\R?[U&NNMMK7N+W-:=6;W%IT_=>5-C6N/N<&#X$_D1FLPQ
M]*PD^0(_@DBA8NOJGP\JO)-C:2X&H@.#I$?2B/\`-5QLR)).H5'IOV$&\8DN
M?N'K%TS/NV_3#6_O_05X<CXA-.^C/&Z'%5^#_]G_[0SV4&AO=&]S:&]P(#,N
M,``X0DE-!"4``````!``````````````````````.$))300Z``````$7````
M$`````$```````MP<FEN=$]U='!U=`````4`````4'-T4V)O;VP!`````$EN
M=&5E;G5M`````$EN=&4`````0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L
M``````MP<FEN=&5R3F%M951%6%0````:`%P`7`!3`$X`1P!&`$(`50`M`$T`
M5P!3`"T`1@!0`#$`,`!<`&(`<P!I`%\`<`!R`#,```````]P<FEN=%!R;V]F
M4V5T=7!/8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O
M9E-E='5P`````0````!";'1N96YU;0````QB=6EL=&EN4')O;V8````)<')O
M;V9#35E+`#A"24T$.P`````"+0```!`````!```````2<')I;G1/=71P=71/
M<'1I;VYS````%P````!#<'1N8F]O;```````0VQB<F)O;VP``````%)G<TUB
M;V]L``````!#<FY#8F]O;```````0VYT0V)O;VP``````$QB;'-B;V]L````
M``!.9W1V8F]O;```````16UL1&)O;VP``````$EN=')B;V]L``````!"8VMG
M3V)J8P````$```````!21T)#`````P````!29"`@9&]U8D!OX```````````
M`$=R;B!D;W5B0&_@````````````0FP@(&1O=6)`;^````````````!"<F14
M56YT1B-2;'0```````````````!";&0@56YT1B-2;'0```````````````!2
M<VQT56YT1B-0>&Q`4@````````````IV96-T;W)$871A8F]O;`$`````4&=0
M<V5N=6T`````4&=0<P````!09U!#`````$QE9G15;G1&(U)L=```````````
M`````%1O<"!5;G1&(U)L=````````````````%-C;"!5;G1&(U!R8T!9````
M````````$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O
M;6QO;F<`````````#&-R;W!296-T3&5F=&QO;F<`````````#6-R;W!296-T
M4FEG:'1L;VYG``````````MC<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``
M````$`!(`````0`"`$@````!``(X0DE-!"8```````X`````````````/X``
M`#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)
M```````````!`#A"24TG$```````"@`!``````````(X0DE-`_4``````$@`
M+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@``
M``8```````$`-0````$`+0````8```````$X0DE-`_@``````'```/______
M______________________\#Z`````#_____________________________
M`^@`````_____________________________P/H`````/______________
M______________\#Z```.$))300````````"``$X0DE-!`(```````0`````
M.$))300P```````"`0$X0DE-!"T```````8``0````(X0DE-!`@``````!``
M```!```"0````D``````.$))300>```````$`````#A"24T$&@`````#.P``
M``8``````````````#T```++`````P`P`#``,@````$`````````````````
M`````````0`````````````"RP```#T``````````````````````0``````
M```````````````````0`````0```````&YU;&P````"````!F)O=6YD<T]B
M:F,````!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L
M;VYG``````````!"=&]M;&]N9P```#T`````4F=H=&QO;F<```++````!G-L
M:6-E<U9L3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)
M1&QO;F<`````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````
M#$53;&EC94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````
M"D53;&EC951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C
M=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O
M;6QO;F<````]`````%)G:'1L;VYG```"RP````-U<FQ415A4`````0``````
M`&YU;&Q415A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%
M6%0````!```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%
M6%0````!```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX`
M```'9&5F875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG
M;@````=D969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O
M;&]R5'EP90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/
M=71S971L;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H
M=$]U='-E=&QO;F<``````#A"24T$*```````#`````(_\````````#A"24T$
M%```````!`````(X0DE-!`P``````[X````!````H`````X```'@```:0```
M`Z(`&``!_]C_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P(
M"`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,
M$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(``X`
MH`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&
M!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'
M!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&
M!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/3"3)U/*B^U
ME;2^QX8P<N<8"D>3\57S?0..1DR*I$D3,_F_0]R2C=:([>K8;&DMMU$07!P;
MJ?WH0W95]K0YMD-.H+-`1_6"#LZ7M)8_P@'GG^4U6&[=C=OT8T^'S3M&/UG>
MA_=:Y-O[SC_:/]Z;>_\`>=_G'^]6#Z?>/E_L4"*_WOO26TC;=<SZ-CA\R1^*
ML8^1?98&.U!!U$CA`&WM'RY1L-Q=>):6P#]*/#^2YR13&[&[<#7R"3^*G)\2
MF2365>3XE,28Y*222F,N\2@9!D-))$3W(_BCN<X2`PGS)`'_`'YRJ93JR&C(
M9`D["UVO\KLB$2.C6M=#_P!&X@1KM)B5'>_]]W^<?[T1U>.1++2/)[3_`-4Q
M"(@Q(/F)C\83F$VIQ<X0YSB/,G^]1KKK;:U[B]S6G5F]Q:=/W7E38UKC[G!@
M^!/Y$9K,,?2L)/D"/X)(H6+KZI\/*KR38VDN!J(#@Z1'THC_`#5<;,B23J%1
MZ;]A!O&)+G[AZQ=,S[MOTPUO[_T%>'(^(33OHSQNAQ5?@__9.$))300A````
M``!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X
M0DE-!`8```````<`"``!``$!`/_A$(9H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS
M>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(B!X;7`Z0W)E871O
M<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!X;7`Z0W)E
M871E1&%T93TB,C`Q-2TP,RTP-E0Q,SHU-CHR-BLP.#HP,"(@>&UP.DUE=&%D
M871A1&%T93TB,C`Q-2TP,RTP-E0Q,SHU-CHS.2LP.#HP,"(@>&UP.DUO9&EF
M>41A=&4](C(P,34M,#,M,#94,3,Z-38Z,SDK,#@Z,#`B(&1C.F9O<FUA=#TB
M:6UA9V4O:G!E9R(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HT0T4S,T8T
M0T,R0S-%-#$Q.#,T.$0S.3A&,48T-3!&,B(@>&UP34TZ1&]C=6UE;G1)1#TB
M>&UP+F1I9#HT044S,T8T0T,R0S-%-#$Q.#,T.$0S.3A&,48T-3!&,B(@>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED.C1!13,S1C1#0S)#,T4T
M,3$X,S0X1#,Y.$8Q1C0U,$8R(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!P
M:&]T;W-H;W`Z24-#4')O9FEL93TB<U)'0B!)14,V,3DV-BTR+C$B/B`\>&UP
M34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C
M<F5A=&5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C1!13,S1C1#0S)#
M,T4T,3$X,S0X1#,Y.$8Q1C0U,$8R(B!S=$5V=#IW:&5N/2(R,#$U+3`S+3`V
M5#$S.C4V.C(V*S`X.C`P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0
M:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(O/B`\<F1F.FQI('-T179T.F%C=&EO
M;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z-$)%,S-&-$-#
M,D,S130Q,3@S-#A$,SDX1C%&-#4P1C(B('-T179T.G=H96X](C(P,34M,#,M
M,#94,3,Z-38Z,SDK,#@Z,#`B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E
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M:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N
M:6ED.C1#13,S1C1#0S)#,T4T,3$X,S0X1#,Y.$8Q1C0U,$8R(B!S=$5V=#IW
M:&5N/2(R,#$U+3`S+3`V5#$S.C4V.C,Y*S`X.C`P(B!S=$5V=#IS;V9T=V%R
M94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z
M8VAA;F=E9#TB+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM
M<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z-$)%
M,S-&-$-#,D,S130Q,3@S-#A$,SDX1C%&-#4P1C(B('-T4F5F.F1O8W5M96YT
M240](GAM<"YD:60Z-$%%,S-&-$-#,D,S130Q,3@S-#A$,SDX1C%&-#4P1C(B
M('-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HT044S,T8T0T,R
M0S-%-#$Q.#,T.$0S.3A&,48T-3!&,B(O/B`\+W)D9CI$97-C<FEP=&EO;CX@
M/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI
M;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#
M('-21T(```````````````$``/;6``$`````TRU(4"`@````````````````
M```````````````````````````````````````````````18W!R=````5``
M```S9&5S8P```80```!L=W1P=````?`````48FMP=````@0````4<EA96@``
M`A@````49UA96@```BP````48EA96@```D`````49&UN9````E0```!P9&UD
M9````L0```"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4
M;65A<P``!`P````D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P`
M``@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y
M-C8M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR+C$`````````````
M`````````````````````````````````````````````````````%A96B``
M``````#S40`!`````1;,6%E:(`````````````````````!865H@````````
M;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/
MA```ML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````
M`````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````````````
M````````````````````````````````````9&5S8P`````````N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````
M```````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="`````````````````````````````&1E<V,`````````+%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````
M`````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ``````````````````````````````````!V:65W```````3I/X`%%\N
M`!#/%``#[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,`
M`````````0````````````````````````*/`````G-I9R``````0U)4(&-U
M<G8````````$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`
M5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!
M`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!
M10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I
M`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"
MP0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z
M`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$
M\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(
M!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('
MY0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD
M";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+
ML`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>
M#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,0
M81!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#
M$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6
M`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@
M&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<
MHQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!
M(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D
M321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ
M**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M
M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z
M,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXV
MZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG
M/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q!
M[D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`
M2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.
M)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/
M5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;
ME5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<
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MEHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*
ME/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>
M0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@
MJ%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R
M2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;
MO16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''
MO\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!
MTT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>
MHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;
MZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV
M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1`
M`````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#_\``$0@`/0++`P$1``(1`0,1`?_=``0`6O_$`-D``0`"`@,!`0$`````
M```````%!@0'`0(#"`H)`0$``@,!`0$`````````````!`4"`P8!!P@0``$#
M`P`%`PL."P4##0````$``@,1!`4A$A,&!S%!46%Q@9$BDM,45!4(H;$R0D-S
MDY345=465A=28G*"(S.S-,0UAL&R)'2THE,VT>&#HT1D)95VUC=7&!$``@$#
M``0)"`8(!`4%``````$"$0,$(3$2!4%189&AT1,4!G&!L<$B,F(50G+2,U-4
MX5*R(T-5%@?QDB0U\(*B8]/#1'0E-O_:``P#`0`"$0,1`#\`_=CF,QD[?)WD
M$%Y)'%'(P,8&0D-!AC<0"Z,N-7$G24!&^?LQY?+WD'@D`\_9CR^7O(/!(!Y^
MS'E\O>0>"0#S]F/+Y>\@\$@'G[,>7R]Y!X)`//V8\OE[R#P2`>?LQY?+WD'@
MD`\_9CR^7O(/!(!Y^S'E\O>0>"0#S]F/+Y>\@\$@'G[,>7R]Y!X)`//V8\OE
M[R#P2`>?LQY?+WD'@D`\_9CR^7O(/!(#GS[F@-8WTH:-.LYD#6TZKG1!M$'!
M7@-5Y/BX<2^5M[OE#&YCY`88?$[J8:KR-416]M*ZNCGHML;-V?NVV0KV\<''
MJKN5#:XDZOF52B9#TD+N#6;C9LQDGBH:^>*PL+>O,3K6TLQ%>H%(C@W'[\TE
MSE5>\28L:JQ8G-\M(KULHN1](CB?>:S+3*VV*B.@;"QM+FX`]_N;=S0ZGXJD
M1PK,=;;94WO$.\+NBW&%M<BJ^=]1`_?;Q9^W&2^(X+Z)6WNUC\)=/60_F^\_
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MO--/O;=.-1ZBV8_TDM_X=5N5?;Y!@T&2TCM[">G.=7Q>6%Q[`6B6#!Z83:Z2
MQL^)<J-%D8\)KC58OUHO./\`2&9>!HNLQE\5(:`BZLK.>$'G_3VUN_1UVJ//
M#O1]VDER?I+:SXAW?<HKFW;ERJJYT7FPXDW^4:'8[>R"\!Y!!)CW/[,1@;(#
MV%HE;G#WH-%K9R<;(5;&1"7D:KS:R3.]V]#>7+W(Z\-H/X98$AIK6<?7#>;Y
MXN/@K/Y,AX/KAO-\\7'P5G\F0#ZX;S?/%Q\%9_)D`^N&\WSQ<?!6?R9`/KAO
M-\\7'P5G\F0#ZX;S?/%Q\%9_)D`^N&\WSQ<?!6?R9`26+WJWBGN2R;*SR,V3
MW:IBM0*@MH>YMP>=`6'S]F/+Y>\@\$@'G[,>7R]Y!X)`//V8\OE[R#P2`>?L
MQY?+WD'@D`\_9CR^7O(/!(!Y^S'E\O>0>"0#S]F/+Y>\@\$@'G[,>7R]Y!X)
M`//V8\OE[R#P2`>?LQY?+WD'@D`\_9CR^7O(/!(!Y^S'E\O>0>"0'5^\.78U
MSW7\NJT5/Z.`Z/@D!&/WPS7N5W(.J]D!/>B&GJH#&=O7O"XU\YRMZC8;4#U8
M"@.OUIWA^=9_@K3Y.@'UIWA^=9_@K3Y.@'UIWA^=9_@K3Y.@'UIWA^=9_@K3
MY.@'UIWA^=9_@K3Y.@-/<4>)6_F$N\-'B=YKVQ9<6EW).V*VQCQ*^.>)K'$S
MV$Q!:UQ&BBG8=JW<C<<X)NJ.9\0YN7B3Q%C7W!2BZT2==*XTS5HXS\4B:#?7
M)$]`L\(3VAB25,[O8_"73UE!\WWG6G?I5\D?LGM+Q#XRY>$10[Z[SV(-2+JR
MM]W;205YR^\P5Q&YHZ-5>*&+!U=N#Y'7U,]GD;[RH;,,V_#XH[$?VH-=!5KI
M_I*RR"3'>DCO#8PDU=:9'=C<V_F:/P67=ON[`RO5<TK>KV[EHGNR+?&I27K*
MNYNOQE)[5CQM>A#]6=JS)_YE;7H(:#B?QLP5W-:Y/BYO=E;VTE,4XNK/<^.U
M,C1[6&SW:BUHW`@CNP5GV.)=BI1Q81B^+:KTR(D,[?\`A79VLC?V3=O1='56
MDJ^2-M:/.2OWZ<7OMYE/B.!^B%CW3&_!73UDGY_OG^83YH?9'WY\7OMYE/B.
M!^B%[W3&_!73UCY_OG^83YH?9'WY\7OMYE/B.!^B$[IC?@KIZQ\_WS_,)\T/
MLC[\^+WV\RGQ'`_1"=TQOP5T]8^?[Y_F$^:'V1]^?%[[>93XC@?HA.Z8WX*Z
M>L?/]\_S"?-#[(^_/B]]O,I\1P/T0G=,;\%=/6/G^^?YA/FA]D??GQ>^WF4^
M(X'Z(3NF-^"NGK'S_?/\PGS0^R/OSXO?;S*?$<#]$)W3&_!73UCY_OG^83YH
M?9,>YXV<7KF(Q?>'GK:ONMG:[NQ3-ZSI<%.RGYJ+%QDZ]A%^6O687-][YN1<
M?F=V/+%03Z8/T%'R7$GTB'ZS\+Q]WGMS[6WRF[^YEU'7H-Q;[N12@=6A4B%K
M`7WF[XM<CDO64V1E^*W5X?BV_%\4[=EKG5M/H*#DN,7IDX\.=%Q0RF5C;7N\
M;8[FOD<!S^+S[MPRBO0*E2H8^Y9:\91?+M=91Y&]O[DXZ;COJ=V*_45FO,[:
M90KWTJO2EQKS'D>)V]-B\:-6[W>W5@[3G[LAI[!4F.[-US588\&N1R^T4=[Q
MMXYQWLY&^<B$OBMVE_Z1ACTN_24.D<7LX1TC$;GGUMW%E\IW=^4CSRZS5_7W
MC%ZO$%W_`"6O_&<__KKTE?\`[=SO_D^Z'_MM/E.[?RD>>76>_P!>^,OY_=_R
M6O\`QFP^'O&CTQ>)]W?6NZO%+(OCQ;;=^2OLC:;FV5E9BZ+Q;M<X[LR3322;
M-Q#6,)HTUHHN5C;FPXQ=_&57J2VFW37](OMP[X_N/XDNWK6[-]R:MTVY35F,
M8[5:?PVVW1Z$N`^G=WL9Z2QU)=\/2:SS10&2QW6W5W/J>EOG#*;NFG7;&%37
M<K=VE8^ZH^64I>A,^DX'A_QDZ2WMX[N\L;-FU^W.WZC=V'WEWRP]OL';];TY
MMY`U[K/.P-Q,2.>-MA@L?%%7G%'*NN.-QU[*$>2-?6V=EB6+N)#8>?D7GQW7
M!OFC"*18;/?K>^2Z@8_/73F.>`YI@Q]"*'0:68*TSC%1;2)UN<Y7()RT5++]
M;MY?G>?X&S^3+42S(CWUWB9027QE'/6&W8[MMAIZB`SH]]LBZ@DN[F,](9;O
M;R]2(.':*`E1O!EW`$9"4@@$'4@T@Z1[D@.?/V8\OE[R#P2`>?LQY?+WD'@D
M!8_.5_J5\:?7ZJ^/5U8OWSQC4\8_5^SU=%/8]1`?_]#]S^>_G%_[ZS]A$@(A
M`$`0!`$`0!`$`0!`$!%9?.8?`PMGR^0M[%DE=DR1VM/-3EV-NP.FD[`HLX6Y
MW'2$6R/DY>-B14\F\H)ZJZWY%K9KK(<7\';ZS<;C\ADGC0'RZEC;D]-7[29S
M?S05*A@W'[\DNDI;WB3$AHL69S?+2*Z:OH*-D.+>]-UK-L(\=B(SR.A@-W<@
M>_7)+0>LU2(X5E>\W)\Q57O$6?<T68PMQY%5\[ZBBW^<S>5<79++Y&\J2=26
MZD$(KS"&,LB`["D1MVX>[!+S%3>RLK(=;^1.7E;IS+0:MD#6R2ZH`!D?[&@!
M[H]'*LR/1<1U0!`$`0!`$`0!`$`0!`$`0`:'![26O'(]I+7BG)1[2'"G70<-
M5K++C=\]ZL3JBRSM]LVT_073Q>P$?@ZER)"!UB%JG8LSTRMJI.L;SWACT[++
MGL\3]I=-2]X_C%EHM5N5Q-C>MT!TMF]]E-U3J.VL!/8"C2P8/W)M>726UGQ+
MDQHLC'A-<:]E^M%YQW%3=6\U6W3[S%/-`?&X-I"TG_O%L9&@=4@*/+#O1U)2
M7(6MGQ!N^[17'*V_B55SHV%;W%O>0175I<0W5M,W6BN+>1LL,@Y]5[214<XY
M1SJ,TXMQDJ,NH3A=A&Y;FI6WJ:=4SV7AD$`0!`2V&_?#[R_^\Q`6I`$`0!`$
M`0!`$`0!`$`0'A<_N\OY!0%>0!`$`0!`=2]K>4@?\R`\C..8$]?0@-8[^XVR
MR=WBI;R(R^+VUTV-@D<QE'S1..N&^RTM4S&G*,9[+UM%#OG'M7YXLKL:T32Y
MT56"SM+44MK6W@ISQQ-#N_H7>JMS;EK;9`A9LV_N[45YC(7AM"&+U,T#O3_Q
M+F_\Z?V<:L\?[FWY#A]Y_P"X9?UR"6X@!`$`0!`$`0!`$`0!`=961SL,4\<4
M\1!!BGC9/&0>4&.5KV>HFIU6AB24TXSBI1XFJKI*9E.'.Y66+GSX*"UF=_VC
M&/DQ\@)]L6PNV+CUVK?#*R+>JZVN725&3N#<^55SPHQGQPK%]&CH-?9+@?:.
MUG8;/W$/+JP92V;<,'4\8MS')0=):5*AO&7\2TGY-'0461X-M.KP\Z2Y)JJY
MU1]!]%>BQN5FMTY-_&Y(6LT=V<#XM-9S;5LFQ&1$A=&]K)(B-<:"%4[ZR+=]
M8NQ5-5K7S'?_`-M-SYF[);Z61L.,G:HXNM:;5=&AK6?6Q!;H<"T]#A3UU1GU
M4X0&78_OEO[Y_85C/W6;+7WD/*6Y:":$`0%TA_51>]L_NA`>B`("V>Y_T7_%
M(#__T?W/Y[^<7_OK/V$2`B$`0!`$`0!`$`0!`=FL>_0QCGD<H:TN/J`H>I-Z
ME4ZD$&A!!'*#H(ZX0\Y.$^3.($LLN^^\6UD?)L+MMO#KN+A#!'#'J0Q`FC(V
M]`T5TJYQJ=WM:-:J?/-\-O>F8VZTE1<B26A%16\K0@'6T'I0$+=8>.5SI(7[
M)[B2YI%8R3I)`!#FU/70$5+BKV.I$0D`K^J<''EI[$T=I0&`^-\>B1CHST/!
M;Z_70'5`$`0!`$`0!`$`0!`$`0!`$`0&[.#$TVVW@M-J_P`5;!97+;?6)B9<
M/FEC?,QG(Q[V-`)'+SJOSTOW3I[6DZGPQ*6WFV]I]GLQ=."M7I-ZJO.L"`]8
MK>>8TBAEDZK6&G7UC1M$!(Q8:[?0R;.$$<A=KN'4+6:`>R@)RRL(K,$@E\KA
M1TA%-'+1K1[%M>N4!G(`@"`(`@"`(`@"`(`@"`\+G]WE_(*`KR`(`@"`QYG$
M4`-`0:]5`8Z`("D;W?KK'WB?]HQ2L?W9>5%1O3WK'G]13U(*T(`O#QZF:!WI
M_P")<W_G3^SC5GC_`'-OR'#[S_W#+^N02W$`(`@"`(`@"`(`@"`(`@"`("Z[
MF;YR[H2WI%@R_M[\0"9FV,$T;K<OU'0OU7L-1(:AP[*C9&/VZC[5&BXW1O>6
MZIW7V"G"=*JM'HXN<W!8<5=T[X".^\>Q3G4!\;M]O`T\E1/:F35ITD!0)X=^
M/NI2\GZ3K;/B?=5Y4O*=J7*JKG1*8+>W=/>=A?NYO1@,Y1SFNBQ^5M9;ECFN
M+2R2T?(RZ:\$4IJ+7<L7[.B[9G'RITY]1,P=Z[JWDJ[OWG8O_5FF_/%M-<Q;
M;-CF7MNU[7,=M.1P+3R'F("CS:V7I+2VFKL$U1U+9ST&D]`TGM#2M),,J.RN
MY::L#P#3NGC4;0\_=4*`SX\/(:&65K1SA@+CUJG5'KH">:T-:UHY&@-%>@"@
M0'*`("V>Y_T7_%(#_]+]S^>_G%_[ZS]A$@(A`$`0!`$`0$/G-XL!NQ8.RF\F
M:QN!QS7B/QS*7+;:)\I!<V&$'6DGG<UI(8QKG4TTHL[=NY=EL6H.4N)$;+S<
M/=]EY&=E6[-BM-J3HJ\2X6^1&@]X?2OX38?7CP[\]O?<MJ&C$XTV-@YPY*Y#
M*.@;J'I#"I]O=.7/W]F"Y75\R..S?[B>'<:L<9WLF:_4CLQ_S3IT(T;O!Z86
M]U[KQ[L[JX3`1&NI<9.:?.7H')4QCQ2R:ZG4>%/M[GL1^]NRD^30O6SD\W^Y
M>\KM8X&[[5F/')NY+U1])I'.<:.*V\,NTR&_6=B:':S+;%7`P]I&>;4@QS8!
MHZI*FPPL2VJ0QX^?2^DY3+\4>(<Z5;^][R7%!["7FC0G-WO2'XO;N[.-F]<N
M9MHP`VUWCM8,NW5'M1<2".\;UQ)587-WX=S2[-'\.C]!+PO&OB3"I%;Q=VVN
M"XE/I?M=)4\OZ65Q+O;G'[T[F12&6^K+=;NY`QN'Z*,%PL<B'`DTY!*I-O=*
M5FWV5[@X5ZT1LC^X,YY^3+/W:JRE5NW+D_5EUE^P7'_A5G=2,[P28&Z>!_AM
MXK*?'@.YVB\8V>S-#SZP"T3W?EPJU;VER:>C66^+XMW!E47?':F^"Y%QZ=*-
MPQ30W$4<]O+%/!-&R6&>&1LL,T4C0Z.6*5A<R2-[34$$@A0VFFTU1G11E&<5
M*$DX-536E-<C/1>'H0!`=7-:\%KVAX(H0X!PIV:H#!EQEG+[D&'IC)9R]05;
MZB`CY,&-)AN".6C9&5`Z!K-.GM("/EQ5[$*[(2@<IB<'4%.4@T<.1`8+V/C-
M'L<P]#FEI]4!`=4`0!`$`0!`$`0!`$![1V\\OZJ&1_26M-!V30(#>W!3#W;[
M[>'7V<+?$<?77=K/H;F8^Q96G;4#/7LVGP59T_AC[[-^I'TL^BH\'"W];-)(
M><-`C;_:[UE7'7$C'8VD6EEO'7I<W7/-IJ_6(.A`97-0:!T#0.UR(`@"`(`@
M"`(`@"`(`@"`(`@"`\Y6;2-[*TUFD5I6G8T("'?8W#.1HD&GV#A717VIH>9`
M8KF/8:/:YI'2"/70'5`$!C3\K>L?70'@@"`I&]WZZQ]XG_:,4K']V7E14;T]
MZQY_44];RM,>XN[2T;KW=U;VS>F>9D?::XZQ[`7J3E[J;,+EVU:5;MV,5RM(
MK-YOQN_:U$4\]_(![&SA=J5YAMIMFRAIRZ5NCCW9?1HN4K;V^L"W51F[C^%:
M.=T-/Y.]=D\C>Y%T8A-Y.Z;8AVL(P0&M;K'V1#6BIZ5/A#8A&%:T1R>3>>3D
M7K[C3;E6G$82S-`0!`$`0!`$`0!`$`0!`$`0!`<CE7AZM:/@BX8V._NIHM:&
M9MY=%LT#W03`^,2:1+$62`]E=+'W(IZJ'Q"24;UR<=$]MZ5H>M\*TGTSZ-W$
M/?R7BYPYW6N-[\]>;N97>*&SR&(O[Z2^M;BU-K=/V-;K:S1,UF`]PYO(JC>N
M)B]RR;RQXJZHU32IP\A]!\">(-^KQ)N3=TM[7Y8-R\HRA*3DFJ/1[56O,S^R
M<<,40&SC8SJM:T'KUI6NA<0?IY:CT0!`$`0!`6SW/^B_XI`?_]/]S^>_G%_[
MZS]A$@(A`$`0!`$`0'Q_Z9+6NW/W'U@'4WKR!%16A\RRZ157.Y?O<CZB])\S
M_N>D]V[HJO\`W$OV&?S]5\?'`@"`Y8UTK@R)KY7G0&1-=(XGJ-8'.*:M+U!)
MR=(IM\FGT&L,MPYWVS>\N7DLL!<QV\EY5MWD'QX^V+=FSNP9W"5S1U&%3(9>
M/;M04KGM):EI*^]N+>V7E7I6L.2A77*D5TZ>@LV-X!9"9H=G]X;*UC+>[ML5
M:R7LI!&EIGN3%"".D-*U3WC%?=6FWQMT]!8V/!EZ5'EYT8KB@MI\[HC^C6XF
MZ>)Q.YNZV/B%Q<QV6!Q]K'+<24D>R**C7/;%JL#CSTT+G+^1<G>NRT)N3/M6
MZ=U8F/NW`LI2DHVHI-OB7(6PX3&D4\7U>JV20'^\5J[6YQE@\#$:IV-/(V8$
MV[<#JFWN98CIHV1K96]L:KEDK[X8HCSW9;=7;NM/ETKK(J;`9&+2QL5R.F)X
M:ZE?P)-4U[*S5Z#UZ")/=V3"NRE)<C]3(N:">W-)X98ORV.:.W2A6Q-/4R).
MW.VZ3@T^5'B#7D7I@<H`@.CF,>*/:UXZ'`.'^U5`84F,LI*G8ZA.FL9+--.C
M2WU$!'RX/E,-QUFRMK_M-I7LH".EQ=[%[D)!2M8G!_)R]SH=5`83F/8:/8YA
M',YI:?5"`ZH`@/6.":7]7%(_JM:2.WR("0CP]X_2_9Q#\9VL>;VK*^N@,^/!
MPMIM9I)".4-I&#V>Z*`D8K&TATL@96E-9PUW=M^L@,H"@H-`Z!H"`W-P8_F&
M\?\`D+#_`%,R@Y_N6OK/T'3^&/OLWZD?2S?BK3K@@"`(`@"`(`@"`(`@"`(`
M@"`(`@"`(#@@'00".KI0&.^TMW\L8!Z6]SZVA`8S\<TU,<A!Y@X5'9(H4!%7
M=I-&YHHUPU206GJTY#0H#!V<E::CJ]8H#T%O*>8#KG_DJ4!I3B_G[S=VXP<-
MI#;327EI?2&:?:$1"*XA8`V)I`>7:U:DCD5C@V5=5S:>A-'(^)]X7<*>'"U;
MBW*,G5UT4:6HT!>;TY^]J)<C+$P\L=J&VS".@F,!Y'YRLXV+<=4:^4XN[O/.
MO>]D-+B6CT:2!>3(XOD<Z1YY7R.<]QZ[GDE;EHT+406W)UDVWRZ3A#P(`@"`
M(`@"`(`@"`(`@"`(`@"`(#D<J\/5K/@JZ_>[O_-W7[>1=+'W8^0^(S^\N_7E
MZ6;G]&S_`.>^%/\`ZK@_T=ZH&]O]NR_J^LZCP+_^Q\.__(7H9_<=<`?K5:D$
M/0@"`(`@+9[G_1?\4@/_U/W/Y[^<7_OK/V$2`B$`0!`$`0!`:*X_<+\YQ3W9
MPN/W?OL99W^#R\^4V.5?-#;WT4]B^S=#'=1,E\6F87!P+FEKN30I^[\N&)<N
M2N1;C*--'`<CXQ\/Y?B'!Q;.%=A&_9N.5)U2DG&E*JM'PZ50^$LGP$XL8FX?
M#=;IS2QLJ3?6%Y:7]AJ@T+MO;R.D`YZ%@/45Y'>&'-55Y5XGH9\EO^#?$N/-
MQGNQN/ZT9*4>=:>@QK3A3?!^KF,K#8.![JVM[>22X'XI?<"%@/YI63RH_0A7
MSBSX8O-TRLJ,.1)M]-$7"QX<[K6>JZ:VN<G(*'7OKAVH3U((-E'3MK3+)NMZ
M'3R%O8\/;MLI.<)7)_$]',J(M]K8V%@P,L[.TLV#FMX(HN3I>UH>>R2M3<I>
M\VRWM6+%A)6;,(+D213[V"YO<M>1VEO<7<AGH&V\,LQ/<M_`:X+9%J,%5I$"
MY"Y=OS5N$I.O`FR=LN'^]-]2MBRP8[W3(3,AH.G9,VLQ/4H%A+(M+Z5?(3+>
MY\^Y2MI07Q/U+2?0&)LW8[%X_'OD;*^RLX+9\C`6LD=$P-<YH=I#2>2JKY/:
ME*2X6=?8MNS8LV6ZN,4J^0D%X;0@"`$`BA`(/,0".T:A>#6J/48$V+Q\]3):
MQAQ]O%6)W;90'M+-7)K5(CW,3&N)[5I5Y-'H(F;=J$U-M=2Q\M&3-;*T='=M
MU7K8K[X8HASW7!U[.\UY=)%38'(Q5+613M'(8I`''I[B34*V*[!\+1%GN_)A
MJ2DN1^HBY89H"1-#+$1^&QS1S\Y%-%%L33U,ASA.VVIP:?*CR!!Y#7K(8G*`
M(#JYC'BCV->.AS0X=H@A`8KL?9.K6VCT\M-8=/0ZG.@.S+*TC-66\0/3JZW/
M7VQ=32AZ9(``H!0#D`T`(>'*`(`@"`W+P8_F&\?^0L/]3,H.?[EKZS]!T_AC
M[[-^I'TLWXJTZX(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`C;[V<?Y)]=`
M8*`(#6?$CAZ=^+:RGL[]ECE\6V=EJ+EKGV-W!<.8^2WG+`9()-=@+)`"!I!%
M%+Q<KN[DI1K!\6M%!OW<OS:W:G:NJ&5;K2ONM/6GPI\3/FG*\-M]\/K.N=W[
MNXA96MQC2S(PT'/_`(<NE`T<[`K:&7CSU74GRZ/2<)D[AWMBU=S"E**X8^TN
MC3T%'D#H9#%.Q\$K31T4['PR`CE!9*&NJ%(5'J=2IDG![,TU+B>A](7IX$`0
M!`$`0!`$`0!`$`0!`$!P7-'*0.N?6052X21L\3E,@1XCCKRY!Y'QP/$?7VKP
MV.G96$KEN'O32)%K%R;].QQYR\BT<^HF9-R=Z(V:YQ4CP!4MCFMY)`/R&RU)
MZRU+*L/1VA,EN;>48[7=F_(TWS5*]<6MU9R"*[M;FVD)H&3P2QN)Y*`.:*]A
M;E.,E6,DT5\[=RS)1NVY1?*FCY/W>X,<6-][NX=NSP^WFOK:2[N:7\^/?C,:
M&F>2CS?9,VEN64TU!.A7=S.P\>*5[)@G356KYE4^68/A;Q'O:Y-X&YK\X.3]
MIQV(ZW]*=$?<WH\>B)G=R-ZL3Q#XCY.QAR>`E=>;O[JX.X-[L\B^&2%E_G,J
M&LMW,M62N++:`.#GD%[Z"BY_>>^K=^S/&Q8-PEKD]&CB2Y>-GUSP3_;3+W5O
M'&WWOW(@K]EMV[-M[5)4IM7)ZM%72,>'6S[\7.'V0(`@"`(`@+9[G_1?\4@/
M_]7]S^>_G%_[ZS]A$@(A`$`0'BZXA96KP2.9O='U-"`QWWS1[!A/5<:>II/*
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M01:S-`0!`$`0!`$`0!`"`11P#ASAP#FGK@@A!KT/2B/GQ..N/UEJQKOPX:PN
M[;*`]I9*Y..J1'N8F-=KM6DF^+1Z"*FW;B.FWN9&?B2M$@[]NJY;%??#$ASW
M7!_=W6O+I(J;!9&*I9&R<#GB>-8_F/U3IZ-*V*[!ZW0BSW?DP]V*DN1]9%21
M2PNU)HI(G?@R,<T]BHH5L33U.I#E&4'LSBXOE5#HAB$`0!`$`((Y01UPA[0(
M>&Y>#'\PWC_R%A_J9E!S_<M?6?H.G\,??9OU(^EF_%6G7!`$`0!`$`0!`$`0
M!`$`0!`$`0!`$`0!`$!S(!#&Z:=S+>%HJZ:X>R")HZ3)*YC*=E%I=%I8?LQ<
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MX;.PTOK#%9J!PT.GM[:\T'G;,`96]AP6$93MOV9.+YB3=Q\;,A2]8MW8<J4N
MG7TFNLKP7W$R!>^TM+[!S.J:XR\>8`[I\4NMM$`.@44N&?DQHG)27*BCR/"N
MY[U7;MSLR^!Z.9U1KC*<`\I%K.PN>LKYNDMAR4$EE,>@&:';0$]6C0I4-Y1?
MWEIKR:2BR/!V1&KQ<R$UQ26R^=51K?+<.=^,,'ON]W+Z:!E2ZYQP9D8`![;6
MM7/>&]=H4NWE8]RE+J3XGH*/)W'O;$J[F#-P7#'VET=127G9O,4H=#*#0Q3,
M=#(".4&.0->.TI"TZM**EZ&U)4EQ/0^DY0!`$`0!`$!P2`*D@`<I.@(-6EF?
M98O)Y%P;88Z]NJ\CHK>39_".#6>JL)7+<%6<TC?9QLF_3L;$Y>1.G/J+=9<.
MMX+FCKKQ3'L-*B:;;2@<_P"B@#@#U"X*/+-LQ]VK+2UN#.G1W'"VN5U?,BV6
M?#/%14.1O[R\=_NX-2TB<><=SKS$?G*-+.N/W(I(L[/A[&C1WK\YOB7LKULO
M.+W-Q=J`<;N_#44I<30[>2M>4S7)=IYU&GD79>_=9<XVZ<>U1X^`J\;5>EEQ
MBP%X\`2R0P,YF`F2G4#&:K&TZZC[<>`M88-UI;<E%<_Z"2AW>LF4,SYISS@N
MV;#V&::=E8]I+@)$<&RO>;;YB6BL[2`-$5K;C5(+2Z)DC@1R$.E#R".D+%R;
MULDQM6HJD;<:>2OI)UN1O10.N))6MT-;,=HUHI0!H=[$#J+RAM;;I5U,IF5=
M2DD0.@:6$BO5(=5#PS&9"U?0%YC)_P!X"`.NX5:.V@,MKFOTL<UX_%<#Z@TH
M#L@"`(`@+9[G_1?\4@/_UOW/Y[^<7_OK/V$2`B$`0&#>[35;2NS]M3DUM--;
MGY.P@(U`$`0!`$`0!`$!JO>,1>>+PQ.D+S(-NV1K6M;+J,KLGM>XO81TM:05
M-M5[.-=7`4&9L]XN;#=:Z?T$(MI%"`(`@"`(`@"`(`@"`(`@,2_\4\5D\>U/
M%]4^S]EK4.KL?;;36Y*<Z]CM;7L:S7?[+LI=XIV?+ZN7R&MQR<_9Y:<U>K3E
M4TY=:M)R@"`P,@_*,A_\)M<=<W))%,G?75C;L%-#M:TQV1ED)/**,H.=91V*
M^VVER*OK1JNN^H_N(0E/XI.*Z(R-1;RGCFZ.0XIN[D45#1F[TC9[T-Z&R9N.
MVE+J?@L"FVOE]5M[=>75T%!F?U*XOL5:4?\`MZ9<\J/H->X'[_O''[`Y\#:?
MI_K`+(X_6KI_?G!NK[WS<BE7/EVRZ[.K@U]!4XO]5=I[/;:]/:4V>GU&]\-+
MQ)8V,9ZRW+N`:;1]EE,M9W(&BIV<>'O[-S@/P7`55=-8O\.5SSI=:9U&/+?"
M2[U;QFN24D_V&ND^J>#0L`,X6/NG91T5F;ICXHV6<5IM)-BVVD;-)+/*9:ZY
M>V.@I0%4^?M?N]'L:?+YSO?#*M5RJ.7>**NCV5&KI1U;;KKJER&[U7G5!`$`
M0!`$`0!`$`0!`$`0!`$`0!`$!V;J^V+@/Q6AWKN:AZJ<.HB,I+G6,(P=AAKJ
M2G<OS&7O[&,'I,=AA,B\C\X+."MU_>2DER)/TM$;(EEJ+[I9M2E\<Y17-&$O
M2:6WF'I!2%WB+L':V)UM<[F,M[_*LCH=$(S[\;<2O/4+%.M?+5[VTY?%H7_3
M4Y;/_K*3_=NS&SP]A24_-VC@V^8T7DVXMMY3B9+Q1GFUNZ=O/;W5KC*]1F.N
MKR/9U_&I13X]KLKN:L)?"ZOI2.9N+`5S_P"_GO&4Z_Q4XP_Z)2])LO=K[MO-
M<_F/S+XEM6;7Q,R[;;;,TVNC;[75Z=-%!N][VUVVUM\O$=-N_P#I[NTNX=CV
M5=.S6M>7AJ>=V-W2X^*ORC/R8H98NP)YH90$CVG#0PNK`=>R=Q>9-=+1"NU0
MXAI+FU[ESFACB.ES`YX:>R5GY2(Z5=-1PO3PX-*'6I3GKR=FNA`95AX_MAYJ
M\>V]='F_;ZW9V/<TZZ\ELT]NE.4SM=KM?Z?;VOAKZC:&'^\6C-ILS#04&:V(
M=JZ.>.MV-'442?=O/R?\4.@QOG=---GXZ?XE]LWY8@#(6V,:>=]E>W;O^KN+
M!E._4>6Q]%OSK]);VWD?QH6_^63]<?62C=:OZ(R:WXH-:<^EI)6'E)"K5;-:
ME9WD^I_B[_K=]6]EJFOGCQ+;4H:ZE?\`$ZW6TK=:[>O[C;KR5*_.^5[+^9=A
M3X]FO6?.&\@X(%[QBW9V.6I[O=QCYK,'3[&/,206Y%?P7!6EGYA]+9I\6OH.
M'S_Z3;_T[O*7_:TQYIT7,S4V1CQ+'DXB\REQ'70W*XVSLY`*\ADLLM?,<:?B
MA3H.Y_$BEY&WZ4CF[\<9/_37;DE\<8Q_9G(C6ZU.Z`!_%<7#U6M69H.R`(`@
M+3N7YM^L5IYT\6\7V<^R\<U?%_&]0>+ZVO\`H];6KJZVBJC9.WV4^SK71JXN
M$L]T=AW^SWC9V*.FUJVN#7HKQ5/HZ,5:W6<60Z*&!C)&4_%#7Q1=I4SUZ=9W
MBU:_9Y/\4B2MQA@1MW7KM/*]C&1]D0OD?3LK%[?!0DV^YU6VYORZ%T-EFL?-
M%!XEXIK?F[6O_2]W7K+7+:^E4LK7=:?N=CU].DE-.CHYNCL<RQ)#KPG"'@0!
M`9"`(`@.S-?7&SUM>HIJ5UJZ*4U=*`MC*ZC=:M=5M:\M:"M>K5`=D`0!`6SW
(/^B_XI`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g911284g68q31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g911284g68q31.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`"4`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]1;G4OL\S1^7NQCG=C^E1?VS_`-,1_P!]_P#UJK:G_P`?C_0?RJK0
M!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_Z8C_`+[_
M`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS_P!,1_WW
M_P#6H_MG_IB/^^__`*U9E%`&G_;/_3$?]]__`%J/[9_Z8C_OO_ZU9E%`&G_;
M/_3$?]]__6H_MG_IB/\`OO\`^M6910!I_P!L_P#3$?\`??\`]:C^V?\`IB/^
M^_\`ZU9E*,9%`%AO$^&(^S=#_P`]?_K4G_"4?].P_P"_O_UJYR_OH+!6>ZD5
M,Y*@GEOH*Y;4_%$UR"ED&@C/4Y^8_P"%5&-S&K7A#=ZG>ZE\0[;3%(EMR\N,
MB-)<G\>.*RA\601D:5_Y-?\`V->>$DDDDDGKFDK3D1PSQ<V_=T/1?^%L_P#4
M*_\`)K_["C_A;/\`U"O_`":_^PKSJBCD1'UFKW_(]%_X6S_U"O\`R:_^PH_X
M6S_U"O\`R:_^PKSJBCD0?6:O?\CT7_A;/_4*_P#)K_["C_A;/_4*_P#)K_["
MO.J*.1!]9J]_R/1?^%L_]0K_`,FO_L*5/BPA=1+IC*A/)6XW$?AMKSFBCD0U
MB:O<]BM?&<-['OMH5=>^)>GZ5-_PE'_3L/\`O[_]:O';:ZFM)`]M(T;CNIZ_
M7UKI--\5(X6/40$;IYB_=/U]*B4+;'72Q49:2T9WW_"4?].P_P"_O_UJ/^$H
M_P"G8?\`?W_ZU8,;K*@>)E9&'!!SFEJ#KZ7-W_A*/^G8?]_?_K4?\)1_T[#_
M`+^__6K"HH`W?^$H_P"G8?\`?W_ZU'_"4?\`3L/^_O\`]:L*B@#=_P"$H_Z=
MA_W]_P#K4?\`"4?].P_[^_\`UJPJ*`-W_A*/^G8?]_?_`*U36_B#SRW^C[=H
M_P">F?Z5SE6]/ZR?04`;O]L_],1_WW_]:C^V?^F(_P"^_P#ZU9E%`&G_`&S_
M`-,1_P!]_P#UJ/[9_P"F(_[[_P#K5F44`:?]L_\`3$?]]_\`UJ/[9_Z8C_OO
M_P"M6910!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_
MZ8C_`+[_`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS
M_P!,1_WW_P#6I#K849:(#_@?_P!:LN1_+7(&:K/(7.6H`V#XB':#/_`__K4?
M\)%_T[_^1/\`ZU8M%`&U_P`)%_T[_P#D3_ZU'_"1?].__D3_`.M6+10!M?\`
M"1?]._\`Y$_^M1_PD7_3O_Y$_P#K5BT>M`#-2^)']G7LMN=.\SR\?-]HQG(!
MZ;?>JW_"UO\`J%G_`,"O_L:Y3Q+_`,ANY_X!_P"@BLL^O:MHQ6AYE3$5%-I,
MZW5OC-=Z<IDM_#OVN(#+%-0PR_5?+_E6`/VE\D`>&R23@#^T>_\`W[J*VL);
MC!`")ZFEN/"]B-]Q#!&MV%XE"@%C5KV2T:.:I+&O6%2R]%_D=#I_QKN;N/?<
M^'OLJD94-J&6/U'EC%6_^%P_]0C_`,G/_L*\X)Z4E-TX=B%C*Z5G+\%_D>D?
M\+B_ZA/_`)-__84?\+B_ZA/_`)-__85YO11[.(_KM?\`F_(](_X7%_U"?_)O
M_P"PH_X7%_U"?_)O_P"PKS>BCV<0^NU_YOR/2/\`A<7_`%"?_)O_`.PH_P"%
MQ?\`4)_\F_\`["O-Z*/9Q#Z[7_F_(](_X7%_U"?_`";_`/L*HZC\;KJR7?!X
M<-S&!\VV_P`,/P\O^M<+2AJ:IP6Z%+%UVM)V^2_R-\?M,#OX<(_[B/\`]KH_
MX:87_H7?_*C_`/:JXS5/#]KJ8+%1%,>DBCK]1WKD=3\/76F$ET\R(?\`+1.G
MX^E;0I4I=#SJN.S"GKSW7HO\CV'_`(:87_H7?_*C_P#:J/\`AIA?^A=_\J/_
M`-JKPS'%&*OZM2['/_;&-_G_``7^1[G_`,-,+_T+O_E1_P#M5+_PTPO_`$+O
M_E1_^UUX7BN^\%_#@:M;0ZAK#LMK+\R01\,Z^I/8?3FIG1HQ5VC?#X_,:\^6
MG*[]%_D>A:3\?[W6[GR-,\*23-_$?[1PJCU)\K`%=U;^-9'A4W-@D<I'S(ES
MO`_':/Y5RUCI]MIELL&GP1P0KT5%Q^?K4]<<^1_"K'TV'A7BOWL[OT2.JB\6
M>:#_`*+C'_37_P"M4R^)03AK<J/7S,_TKF;3HWX5;K)[G4MCHAK8896($?[_
M`/\`6I?[9_Z8C_OO_P"M7.JQ1LJ<&K4-QYAVL,-_.D,V/[9_Z8C_`+[_`/K4
M?VS_`-,1_P!]_P#UJS**`-:#53/,J>5MW'&=^?Z5H5@V/_'W%_O5O4`8>I_\
M?C_0?RJK5K4_^/Q_H/Y55H`****`"BBB@`HHHH`****`"BBB@`I0,TG0<]JQ
M]3\3P6>4M?W\HZ[?NC\>]-)LF4HQ6KL:TLL<$9>9U1!U9C@5SNJ>*PKE-+&[
MG'FL/Y#_`!K"O-0N-1?==R,P!X4<*/H*@QCI6B@CSZV+E+2.B,RYN9+N9I+E
MVD<D\L<U%2GJ?K25?2QR!1110`4444`%%%%`!1110`4444`%%%%`BY8ZK<Z>
M3]GE(4]48Y!_"NIT[Q';7VU)3Y,Q_A)^4_0UQ5`XS[U+BF;TJ\H:'I=%<3IO
MB*YL"$D8SQ=-C'D#V/\`C75:?JUMJ2`V[X?',;<,*AP:/1IUX36^I<HHHJ#8
M****`"K>G]9/H*J5;T_K)]!0!:HHHH`****`"BBB@`HHHH`****`"BBB@!ES
M_JQ56K5S_JQ56@`HHHH`****`"@#)XHIK-@\4`<=K]N]QK=P(@3]S)QP/E%)
M;Z:D6#+\[>O85JZC_P`?LA/?'\A5:MNAYSI+F;`<#`IDOW&_W33Z9+]QO]TT
M%2V..-)2M25NMCQY;A1110(****`"BBB@`HHHH`*&PP(8`@]11136@&%JGA.
MWO`9+'_1YO3/R-^':N2O=.N-/EV7<;(W8GH?H:]*ID]O%=1&.XC1T/4,,U<*
MC3U.6KA(SU6C/+Z]]\%?\BII7_7LM>5ZIX-*AI-,?/<Q.?Y'_&O5O!T;1>&-
M-212K);JK`CH:6(:<4S?):,Z>(ES=OU-FBBBN0^H+5IT;\*MU4M.C?A5NLWN
M4M@J6V_UP^A_E452VW^N'T/\J0RW1110!8L?^/N+_>K>K!L?^/N+_>K>H`P]
M3_X_'^@_E56K6I_\?C_0?RJK0`4444`%%%%`!1110`4444`%+24HZT`<SXKU
M1PPL[<E1MW2D'KZ"N;"@=!6AXA_Y#MR!TPO_`*"*H5NMCQZ\W*;N%!.!D]J*
M#R#3,C(8;68'J#25<N;8G+)][J1ZU4((ZT`)1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4Z.1HI`T;%64Y!'44VC&:!IV9WFB:E_:=BLCX\Q?E?'J/\`
M]=7ZYWP;Q#=#MN7_`-FKHJPEN>Q0ES4TP_$#ZFN0OOC#X"TR\GM-1\<>#[2Z
MMI6BG@GURVC>)U.&5E+Y!!!!!Y%97[0?C^]^&/P=\3>(]%@DGO[*V5+9E7<(
M))'6-9B/1"X<_P"[VZU^2$LTD\KRW#O)+(Q9W=LLS'J2>YS7#B\7[%I)79]W
MPKP@LWHSK5:CC%.RM;5[L_:RQOK;5+*"\TV>&ZM+J-98)X)`\<J,,JRL.""#
MD$<5I6`P9"?3%?)'_!/[XBW^O_#G6/#VMB3[+X4N(_LE[*0$$4^YO)+$]596
M/LKJ.,"OK:TO;-R(K:[MYI#D[4E5B?P%=5*I[2FIVW/E\XP7]G8^IA)R5XO[
MUNOO5BW1115G`%%%%`!1110`4444`%%%%`!1110`RY_U8JK5JY_U8JK0`444
M4`%(3BE'6FMUH`0\G-!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>
M["F2_<;_`'33Z9+]QO\`=--$RV..:DI6I*W6QX\MPHHHH$%%%%`!1110`444
M4`%%%%`!1110`HKOM$&_2+;=S\@K@5ZUUOA[7(#;16MPPAD0;5+'AN>*BHKH
M[L%)*;N;+*5//3L:;4LH^7Z5%61ZY:M.C?A5NJEIT;\*MUF]REL%2VW^N'T/
M\JBS5BWB((=ACT%(98HHHH`L6/\`Q]Q?[U;U8-C_`,?<7^]6]0!AZG_Q^/\`
M0?RJK5K4_P#C\?Z#^55:`"BBB@`HHHH`****`"BE^E<]XC\;Z9X=0K/+Y]UV
MMXF!;_@1Z+347+1$5*D*<>:;LCH.N,<YZ4HZUX7K_CS5M>D(:<VMMGY88&*C
M\3G)_E[5=\.?$G4='V0WV[4+4'[KM^\0?[+=_H<UM]7E8\Y9O0YK.]NYUOB+
M_D/77T7_`-!%4*9-XCL?$.J7$VFS!C\H:)OE=?E'53SCWI]5RM+4PG.,I.47
M=!1112)#&:BFMEE'0`^HJ6B@#-FMVB'(R/45#FM=ER#[U7ELU;++P>X]:`*%
M%/>)HSAQBF4`%%%%`!1110`4444`%%%%`!1110`4444`=3X-_P!3<_[R_P#L
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MX&^-`I`/3`3/S*:\^\#>,K_X?>+--U_1&VW6FS"3;T$J='C/LRD@_6NI\/Z2
M_P`0?AW<V<]S:6=UX0G22RO;Z800FVN7.^W,C?+N$N)$!_O3>E3^#OA?!'K8
MO/$&HZ!JVG:7;S7]SI^F:M%//=K!&TGE*JG.&V88CHNX]J]_#TZ.&H>QZ1T]
M3\8SG&9EG6:O,FVY5&I)]O+Y-?J??-C\5?"EWI]E=7>OZ/IK7UK%<K;7M_%#
M-&LB*ZAT9@P.&'&*Z+3=5LM9L4O=(N[6^LY03'<6TRR1O@X.&4D'!!'7M7Y3
M:_KMYXFUN]U75I/,O+^=I9F`P,D]%'8`8`'8`#M7U%^Q!\0KUGUOP;=I-/9+
M;OJ%I*!D6Q!"R*3V#%E(]P?6O+Q64>RHNI&6W3^NQ]OD?';QV/CA*M.REHI*
M^_2ZZ7_`^L](UO3O$%I]JT#4++4[7<4\^SG69-PZC<I(R/2IK/4+748'FL+F
MWN88G>-Y(9`ZJZ$AU)'&0001V((-?-/[-[?\*XT_P/G,7AWXDZ1#R>4M]9AC
MQ_P'SXAZ\O%[U/IL9U[0/#_@^ZDFBTCQ7\0M?35?)<H;BW@N+R<V[,.0KLBA
ML<E=P[UXQ^CGNNF_$;PIK.KG2M(\3:!>ZF"1]C@U*)Y21U`0-DFMFTU&TOYK
MF*RNK>XELY/*N4BE#F%\`['`/RM@@X/."#7(^,?A)X6\4^#YM&.D:=IZ0PDZ
M?<6=ND+Z?*H_=RQ,N"I4@'@C..>*\K^!_BB\7QEX;U+66;;\4_"L-Q+*W_+7
M5;!1'*P'0>9`5?C^Y0!]`OJ5G'J$5A)=6R7T\;2Q6K2J)712`6"YR5!(&1QD
M@5BR?$KPC%K(TB7Q3X=352_E_8FU.$3;LXV[-V<Y[=:\*\::M<^(?$'C7Q!I
MUS/:QWFLZ9X!TZ^@?8]K`URGV^1#V8O*8PPZ&,>E>W-\*/!A\+_\(X?#.C'1
M?*\LVAM5QC&,[OO;^^_.[/.<T`=/<3Q6D#S7<D<,,2EGDD;:J@=22>U8>C?$
M'PMXBOFLM`\2:#J5ZO6WM-1BFD]_E5B:\(\((?'NI^$O`7B^>75=$\/SZX;I
M+H9&K?V?>);6BR_WU59=Q!R&903G%>^1Z)X;T.]T^2/3]$L+T%H-/9;>**0$
MH24BX!^XK9"]@>PH`JW7Q,\'V5U+;7GBOPU#<0.8Y8I-6@5D<'!5@6X((P0:
MUQKNFMJW]E)J%BVIB'S_`+$+A?.\O^_Y>=VWWQBO$/A=XETFUM=8M+[P;KVJ
M3GQ9K"M?VWA\W,)W:A-_RUQT7.#Z8/I6?\1]&O8/BYXM\9>&(VFUWP+IFC7\
M4"#FZM&^V"[MO^!Q98?[4:4`?0-UJ-J+M;$W-O\`;6B\X6_FKYGE@XW[<YVY
M(&<8S3:\RM=7M/$'QVT74](G6YL-1\`O<VTR])(WO(RI_(BO3:`"BBB@`'6F
MM]XTX=::WWC0`E!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>["F2
M_<;_`'33Z9,0L3LQP%4Y-,F6QQS4E*:2MUL>.]PHHHH$%%%%`!1110`4444`
M%%%%`!1110`9Q1DT44`2W/B^[\.67FH!<P(Z@Q2$_=)&<'M71^'?&>F^)$Q9
MRF.XQEK>7`8?3L1]*\^\6?\`($E_WT_]"%<-&[1.KQLR.IRK*<$'U%:*C&<;
MF,LRJX>KR[KL?4%F<J_L16A'`TG^R/4UP/P6UV]U^UU-=6F-Q]C,2Q,X&0&W
MYR>_0=:]*["N"<>631]/AJ\:U)5([,9'"D62!DGN:?114FX4444`6+'_`(^X
MO]ZMZL&Q_P"/N+_>K>H`P]3_`./Q_H/Y55JUJ?\`Q^/]!_*JM`!1110`4444
M`%5=5U6VT6RDN]0D\N&/J0,DGL`.YJV.M<3\7?\`D6(O^OU/_07JHJ[2,,34
M=.C*:W1R_B7XHWVIEX-'#6%L<C?NS*X^O1?P_.N(8EV+.<L3DD\DTE%=ZBH[
M'R%7$5*KO-W"BBBF8',ZG/)::L\MK(\4B$%61L$<"NK\/_$N2,+!KR-*N?\`
MCXC'('^TO?\`#\JY#6_^0E+]1_Z"*HCK6W+&4=3&%>I2DW%GT#;SI<PI+`P>
M.10R..C`C(J2LSP;;2OX:T[Y=H-NN"W&:VS8R8RNT^V:X)*SL?2TTY13MN5Z
M*4JR$B0%3GO24AO3<****`$90PP<54FLN\9'TJY10!D$%3A@0?>DK4>!9!AN
M:J2V;+DIR/2@"M12D8-)0`4444`%%%%`!113D1I&PBD_TH`;4L<#2'Y>GK5F
M"R`YD.3Z5:`P.*`.@\$6RI#=MU(9>OT-=0.U<[X-_P!3>?[Z?UKHSUK&:]X]
M;#?PD0WMI!J-I/:WL2S6US&T<T3C*R(PP5/L037Q?KW["GB<ZW>_\(SK/AY=
M),[&R%Y<3B98B<JK@1$;@"!D$YQ7VK171AL95P]^3J>;G&08'->3ZU%OEO:S
MMN?G%\9_"-_\)+/2/`]XJLP3^U+^\BSY5].^Z-=A(!*1HI49`.YY#C#"O._#
MVO7OA;7+'5M&E\J]T^9986QD9!Z$=U(R".X)%?H9^T%\"X_C7H5A#:74.FZK
MI=P7M[N2,NIC<`21L!S@X4@]BN.YKR;X??L23^'?&.EZGXLUO3=4TW3YO/DL
MXK=U,[+RBG=QMW;21W`QWKV\/F5'V%ZCUZKN?EN:\&YDLSY<+!NGIRRNO=6F
M]]=#D+[]C'Q-XFN/[8\-76A:/I>JQQWEOIVHSSK-9"1`[0.%B8?(Q9.O(4$\
MU]!?L\?`\_!KPA>6^IS6EWKFJRE[RXMLF,(N1&BEE!*@$MT!RY]J]<Z#`&`*
M2O&KX^O6AR2>A^CY;PIEN`Q'UFE%\_=O37=I=#RFQ^#-Q<?`+2_`NLW-O#K.
ME6$0M+^U9BMK?0MOAF1BH;"R`=AD;AWJEH_P6UR7X=65AK.JV&F^,--\0W6O
M6>H::'GMX;F6>63;M<(SQLLS(R\<'J<<^QT5QGTAYGJVE_$_Q7I,^BZE_P`(
MCX<AO(C!>ZMIM_<74XC(PYMX7AC5'(S@L[;<YPV!3_'/PLN9O!WA:R^&C6%A
MJ_@:[M9]#^VLRQ%(U\IX9&56;:\3,#@')`KTFB@#S'1O@G!!\$;;P+JU](+S
MR1+<:G;/N=;_`,WSS<HQ`)(G^8$X)``/>I5?XLC3_L+0>`A>*OE_VT+RY8$=
M/-^R>2/GQSL\X+N[XKTFB@#RNZ^"<VD^'_"__""ZN;7Q-X1>XEM=1U!&F34&
MN#NNDN0#G;*YWG:<JP!7CBGW'ASQYXI\4^$+WQ;8^%-/M?#.J/>S2Z?JL]P]
MPS6TT&U(WMT"C,V>7.,=Z]1HH`\M\):!X^\$VFIV%AIO@N^L[C6;^^AFFUNY
MA?9<7,DP#(+1AD!\'YCTZ]ZZC2/"MY8?$CQ/X@N'MC9ZU8:=;P(K$NKVYN-^
MX%0,?OEQ@GOP*ZJB@#Q_X:_!G5_`'Q*O]0-WIDOA*WL+BST*UC9_M-M%/<+<
M>4X*A=B/YBJ0Q.-N:];D@S_J_P`JEHH`I$%3AA@T5=*AAAA5>2W9>5Y7U-`$
M0ZTUOO&GXP:8WWC0`E!Z44'I0!AZC_Q^2?A_(56J76+B.VN9&F8*!C^0KG+W
M77ERMH#&O]]NI_PK=1;2/.J58P;N:MYJ$-DO[QLOV0=36#?ZK+>`J/W<1_A7
MO]35-B6R222>22<YIM:*"1P5,0Y:=`HHHJC!NX4444""BBB@`HHHH`****`"
MBBB@`HHHH`****`,;Q;_`,@27_?3_P!"%<*.E=UXM_Y`DO\`OI_Z$*X4=*ZJ
M7PGD8W^+\O\`,]D_9]Y@UW_>M_\`VI7K/:O)?V??]1KO^];_`/M2O6NU>=7_
M`(C/KLJ_W2'S_,****Q/1"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;U`&'J?\`
MQ^/]!_*JM6M3_P"/Q_H/Y55H`****`"BBB@!1UKB?B[_`,BQ%_U^I_Z"]=L.
MM<3\73_Q3,7_`%^I_P"@O5T_B1RX[_=I^AX_1117H'Q@44^*&2XD"0J78]A6
M_I_AI0`^H$,?^>:GC\:3:1M2H3J/1'G]SI-SJVJS"SC+*&`9SPJ\#J:Z32?"
M-M8;9+K_`$F=>02/E7Z"NCNXTBF98E5%'0+P!Q_]:HAT-)U&]C>GA80=WJSM
M=*&-+M<8`"<`=JM56TO_`)!=M_N59KD;N?14_@0UXDE3;(`:IRV#1_ZK#`]N
MXJ]0#BBX3IJ1DY]>"*,UI36T=P/G^5O[PJA-:O">F5]157.65)IC**0$'H:6
M@R"BBB@"*6V249.0?451E@:(\\CU`K3I"@/6@#(HJ_+9J^=GRD56-K("1M)^
M@H`AI5&XX'6IX[-V^\"H_6KD4"Q#Y<Y]:`*L5D>LGY5;2%4&$&!3Z*`"BBB@
M#IO!O^IO/]]/ZUT9ZUSG@W_57G^^G]:Z,]:RGJSU\,OW*$HI<48J#8,=?;FD
M]?;K[50U_2;77-%N['4K:*\@FC),,@R&8<KQZ@@'->=_\(?J>G_!CP]IGAVV
M_L_6Q/HD]X#$6*2I<VQN))%5U+X57+#<,A3SSP`>J`%L8YR,C%)7DVI>'_%+
M^!?BO:Z@_P!NU;5&N#ILEG`\"SYTRVC3RD,CL/WBLOWN64GC-=OX!L$TWPW#
M;QV\-LR2.76'3)-/0L3G*PNS,.W))R030!T8&3@=?2C!':N$D\*WUS\89];D
MCLO[-M=*LXX'N+1I)#+NN]_DR"0",@-'NRC9!'3BLF?3M;/B;^SDL=3VCQ?'
MJHO,?Z.UDL"Y/F9P/G!3R_O9.=NWYJ`6IZA2XYQW%</<>";1_BM::R-,B:)=
M,FDDN]O'VL2Q>6W^_LWX/ID9[5D7EIK`\1W^EQ:9J;+>^*K+48+P+_HZV4<-
MOYF9"<#YX9%\O[Q+`X(;-`'IXY&1TH"E@"O.>F*\D\0>$-=G^*T&MVUNO]EQ
M7]BLDT43?:A&(Y`Q1]^/*WF-9$*G*L2#\HK7@T2X7XR7VHWMK'):O!"MG,^E
MRRL#Y3!RMP'V1C+-E2A))Z\T6`]$`)Z4F<G`ZUS?Q%LM1U#P=?0:"+F2Y=X&
MD@M9O)FN+=9T:>*-]R[7>$2H#N'+#D=1B>`M)>UU_6Y]$TR^T7PU/96RV]E=
M*T&^[4R^=*D)YC!5HE)P-[*6`XW,`=^.1D<BBN'^"_A2]\(_#W2;77([*+4I
M+.W>Z6WM&@82^2@82YD??(&#9?(!/85W-`"444N*%J`E%%%`#3&K9XP3WJI(
MC*YSS]*NU#)]YOK0!5Z].M.$18?,.#4H4#H!3AUH`\V\8$_V_<J22%V8!/3Y
M!6+6SXP!'B&[S_L?^@+6-79'8^=Q'\67J%%%%,Q"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`QO%O\`R!)?]]/_`$(5PHZ5W7BW_D"2_P"^G_H0
MKA1TKJI?">1C?XOR_P`SV/\`9]_U&N_[UO\`^U*]:[5Y-^S^I6VUMB"%9X0#
MC@D!^/UKUGM7G5_XC/KLJ_W2'S_,****Q/1"BBB@"Q8_\?<7^]6]6#8_\?<7
M^]6]0!AZG_Q^/]!_*JM6M3_X_'^@_E56@`HHHH`****`"N:^(6AW.O\`A\PZ
M<HDGAF658^A<`$$#WYKI:1G"''4]Q33L[F=6FJD'![,^;IH)+>=H9XWCF4X:
M-E(8'TQ6MI_AV6?Y[L^2G]TCYC_A7L^J:1:ZLX>ZA1I$4A)0,,H]`:Y?4_#5
MQ8C?#F>(=UZK]1_A74JZ:MU/"EE7LGS/5&!;6<-I'LMD6,'J1U/XU/1VS2JI
M=@J`DGH!2UO=EI):(R;[FX;\*9;V\ES)Y<",[GL.WU]*WE\-22W)>_)B3@[`
M/F/^%;-O:Q6D02W144>G]30YHJ&&<G>6@EG";:SAB<@M&N&QZU+1161Z$596
M"BBB@84`X_&BB@"O+9I)EH\(W\ZIRQ/`V)!QZXXK4H8!EPP!![$9JDS&I14M
M49`8'I2U:FL!DFW/_`355_D;:X(;T(IG+*$HO4****"`HHHH&%%%%`!1110`
M4444`9^O?%C2OA=I\?\`:-MJ&I:EJ]PL&FZ9IT/FW%VXZA5XSC*_F.#72_#7
MXBR^/X-0^W^&O$'AF[TV14EAU:W\OS"P)!1OX@`.>.,CK7G?C7P1XEU37/#7
MB_X=Q6=_K'@^ZG)TV[E$2W<5Q&$<*YX5@JD<D?>SG(P?1OAWK?C776U"?X@^
M'=.\-VVZ-=/M8=1%U-C!WF5E^3&=N,$'J".`3K4A#V*DK7]=5KV,,'7Q+QKI
MU&U!/1*%XM<M[N=M'S75KKIIK<R]7^-VC:-\6=.\!SV]T]]?QJ3=KM$,$CJ[
M)$V3G<P08_WAZ&M#XN_%*R^$/A,:]JUG=7UL;N.W,=L5#98$@_,<8^6O!]>^
M!7Q'U^3Q'XRANK>QURX\10ZE8:%)%"\D@MF*VQ^T^9A=L4C_`"]#CZ5ZE^T/
MX/U[XC_#;3;/P_IHEU`ZI:W5Q:2SQCRD56W@LS;3@D#@G-5*CAU.FD].IST\
M?FD\-BG*DU)7=/W>CO96UNU;5/77;8Z/1?BWI?B+QS8>'=&AGN%U/P\NN6]^
MK+Y1A:0QA",[@V1GVJA\1?C79^!==M=`TS1-:\4^(KN`W']FZ3!YCP0Y(\R0
M_P`()'OVSC(SQ/PK^"&L_#?X[:C?6R^=X-31YH-(E,RDVJRSK-]FVYW#:YEP
M<8((.<G`T_&WA#QCX1^+LGCWX<Z3:>)8=6TM=/U'3)+Q;26,JPVR([_+MPB\
M=<YXYR!TL.JMD[JW>UWYOH7]<S26!<YP<9\]G:-VH]TOM:[/71WUL>D>#/&/
M_"8>%H]9?2-6T5B9%DL=3M_*G1D)#9&>F0<'O7$_##X]O\4]0LAIW@[Q-9:7
M>K*4U:YB4VH*9!&\'J64K]:[+P;=>)M7\*-+X]TW3]*U><R[;.RN?.6*,D[%
M9NF\`X."1D9XS@>'_LV?#+Q+\--3L(?$7@.:TN989X;W7?\`A(TE18RQD4"U
M5B,DJBY'/?N:B%.DX5&]UMK_`,'7\2Z^*QL<3A(POR23YGRZ[QM=<KY;ZZ/E
M]3T3XE?'BW^'/BR+04\-:YK]VVE_VE)_9JH_EP!W5B02#@;"2>G-=UX-\66'
MCKPOIVO:$TC6&IPB2+S``Z\D%6`)`(((/)Y'>O%OC/\`!77?B5\4C>Z;/=Z;
MIO\`PB,EG'?V]ZL.;OS9&6*1<[FC8.`P`P0>M>H?![3;_1?AKH.FZ]I$6AW^
MG6JVTUI%,LJY3C>&4D'=][KG).<]:*U.BJ,91^+J:9?B,QEF=:%>+]EKRZ66
MC75+\]^FS+?Q!\977@C1(]0T_P`/ZSXD=[@1/:Z7$'DC4JS&1A_=&T#_`(%7
M,_"7XV-\67#V/A77M+TQ[9YH=4NT4V\S)($,:L.K9+<?[)KT>[C:6TG2,?-)
M&RCG')'_`-:O/?V=O!VK>!/A!HFB>*;;['J-HUQYL/F+)LW3R.OS*2#PP/7O
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M6^IWT:BWGPRJ$5AU)R3_`,!-9?Q`_:+M/`7B_4]#?PQX@U?^Q;.*\O[JP1'2
M"!@#O8$Y`&>2<"N>_9G\!Z]\.I?L6N^")=$DGLMM]K!\1)=I<.C955MU)\O.
MYNAQQ61\8/@)XG^('Q%\9ZII;W=C;76@PIIDL-^D4=]/'LW6\J[@Q5@&`)PN
M<$GC%:JCAO;R3:Y>FOGY,X:N,SC^R:52G%NLWJN76W*W:SC'2Z2O;RNV?0^@
MZY:>)-!L=8TMRUEJ5K'<P/(NT^6ZA@2.QP:XGX1?''1?C#-K4>@VUS:G1YE7
M-PR_Z1&Q8+(F#T^1LCMWJ'6+/Q*_P%ET[P]X>&G^)'T5;"+28;B)%M&($1V/
MOV[53<ZG=G`&>>*X7X:?!CQC\*/B-X>O?MUIK^CSZ*VE:B]O:1V9L4CP\1*^
M83,2Y(W@;L9S6,:5+DFVU?6VO;_,]&KC<?'$X90IMP:7.U'K+1;ZJSU:MHM[
M'9_$KX[P?#SQ8F@1>&]>U^\.E'4Y#ID:OY<`=U8D9S@;,D^];<GQ5L;GX4GQ
M[X?L;W5M-%H;K[-"56;8I(D&"<93#9&?X3BN#^)OP6U/XB_&ZVU!KO6-)\.#
MPP;*?4-)OXX)6F\Z0F`@[CL9'Y^7!XKUSPKX3T[P;X8L=`T.'9IUA`8HD<[B
MP))8MZEB23ZDFE46'C3A;?J:8669UL57532GJHMI7OI9K2[6^][]#D?"GQNT
MKQQXML-$\*V=Y?+<Z-'JEU>J5$5BL@^6*3G/F$XX]_8UZ,>O'2O(_P!G?X93
M_#:P\5Q:CI<.FR7_`(AGDL_+E20O9*%$`RI.`,O@'D;CQS7K=8XA4U.U/8Z\
MGGBYX6-3%?&^EK6\N_GKW"H7^^WUJ:H7^^WUK$]0;2TE%`')^-="DN"+ZT4N
M47;*H&3@="*XG\#7L58>L>$[35-SQ@6UP?XX^C?45M3J=&>=B<$Y-S@><XQ1
M6EJN@WFD,?M49:/M*@RI_'M^-9P&:W33V/*E"479JPE%!&**"0HHHH`****`
M"BBB@`HHHH`****`"C&:,5>L=(GOB"B^7'_?8<'Z4-V*C!MV*./4@'ZT$8-=
MC8Z5!8K\J[Y"/F=N_P#A2W>EV]ZI$B`,>CJ,$5G[17.KZG*V^IYKXMXT67/]
M]/\`T(5Q=C87&I7<5K80R7%Q,VU(XUR6->T7'PWEUP?9KBZ%O;,RL9`F7(!Y
M`!XS[UV_ASPEI?A6W\O1[98V8?O)F^:1S[M_3I6T<1&,+'$\IJUZW-+2/];%
M7P%X7_X1+P[!:2$-<N?-N&7H7('`]@!BNAI:2N&3;=V?34Z<:<%".R"BBBD6
M%%%%`%BQ_P"/N+_>K>K!L?\`C[B_WJWJ`,/4_P#C\?Z#^55:M:G_`,?C_0?R
MJK0`444O\J`$H9@HY/X4QI>H`_&HCR<GDT`/9R3P<"F444`%'7KVHHH`R]1\
M.VNH-OP89/[R=_J*FT[1[;3`#"FZ0=9&.6/^%7J*?.TB%2@G>VI@:IQ>R@>H
M_D*J5;U7_C^E^H_D*J5HC"6X4444""BBB@`HHHH`****`"DDC25<2<^_>EHI
MW$TFK,HRV+)EHLNH[>E5\_7BM8$BHYK>.<?,"&]133.>I1[&;FBGRV[0.`W(
M/1J93.>2LPHHHH$%%%%`!11FBBP'3>#<>5>9_OI_6NCKG/!O^IO/]]/ZUT9Z
MUE4W/6PW\)!DX^M`)!X.*2BH-P[8XI<GVI**`%SD\_K1T&,"DHH`7<:"Q/4D
MTE%`!2YI**`#Z@?E2]1_/WI**`%SQU/YT9)__7244`*"1CMCICM1DXZGFDHH
M`7/K2444`+G-)12T`%5W/SM]:KZMKMEHD>Z^F4-_#$OS.WX?XUS4_B275HR\
M"F"%R1MW98@$CDU:@VKF4Z].#LWJ;E]K,%H2F?,D[A3T^M4U\3#/S0MM]G&?
MY5@YH!Q5\B.66(FWH=E::A!>)F%_F[J>"*L5PZ2-&P:,E6'0@]*V+/Q"R@+>
M@D=G7K^(J7#L;0Q">C-YXTD0I(JLK=01D&N8UCP5%-NETQA"YY\MLE3]/3^5
M=+!/'<1AH'$BGN*EJ5)Q-9TX5%JCR.]LI[";RKN-HW'KW^GK4!&*];O+&#4(
M3%=QI(A[,.GT/45QVL^"I+?=)I3&:,G_`%3??'T]:WA4ON>57P4H*\=4<K13
MI(FB<I*I1UZJPP132,&M#A:L%%%%`@HHHH`***?%$\T@2)2S-T`%#=AI7&XJ
M:ULIKQ]L"%O4]A6Q8>'#Q)?G'I&I_F:W(XTA39$JH@_A48%0YHZZ>$;^(R[#
M0(8,/<_OG[`_='X=ZUJ='$TIP@)J_!IZJ`9AN;L,\"L92OK<]&E225DBI!:O
M<'Y>%'<U?@LTA&2-S>IJP!M&!Q14.3.B,$@QZ_SJ6.X9.#\R^E144BR^D@D^
MZ1GTI:H`D=#CZ5-'<G@.,CUH`LT4`AAE2#]**`"BBB@"Q8_\?<7^]6]6#8_\
M?<7^]6]0!AZG_P`?C_0?RJK5K4_^/Q_H/Y55H`*;*2%&/XJ=3)ONK^-`$5%%
M%`!1110`4444`%%%%`&#JH(O7)_BP1^0JG70WUDMW%\IV2*/E/;\:PY[=[=L
M2*1Z'L?H:TCL<THM,BHHHIDA1110`4444`%%%%`!1110`4444`-F031,OJ.*
MREX'-;"]:QT^Z/I5(Y*\4FA:***I;F`R:9($+RL%11DL2`!7*:SXZCBW1:0J
MROT,K_='T'>H?B"[JUH@=MC%SM[9&T5QW2NFG25KGGXC$SC)QB='IOC>\MY?
M^)A_I,1.3D`,OTQ7::;K-KJL>^SD#$#YE)PR_A7E%:_A[2[BXU"UD0F&/S5_
M>=\9Z"B=-:F>'Q%1.VY[OX.B86MQ(1A9'&W\.O\`.N@-16UO':P)%`H5$&`!
M4E>?)W9]=3AR040HHHJ2PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*4
M]*1B%&7(4`9))KD];\?VUGNBTD+<S=/,S\B_X_YYJE%O8RJUHTHWDSI[N\@L
M(&FO94AC7J6.*XC6_B!+*Q@T)"`>/.<98_1>U<KJ.I7.JW!FOI6D<]!T`]@.
M@K7\'(IFN6*C>H7:WIG.:W4%"-V>;+&3K5%"&B_$;9^&[B_D\_5WD0.<X9LN
MWU]*Z--'@%LB6X,6T8'.?SJ7-68ON`5+DV=5*A3@N]_O,.XM)+8_O%^7LPZ&
MH:Z1U#(P.""*YS&,^QH1G5I\K$H!Q113,R6WNY;5]T#E3W]#]:WK#Q!'*`EW
MB)^@/8USE`XJ7%,N%64-CNE(=05((/0@TM<?9:E-9']TP*=T8<&N@T_5X+T!
M0?+D/\#\?D>]9N+1VPK1EOH-U70K35T/VF/$F.)$&&'^-<3J_A2[TS=)&#<6
MX_C1>0/<5Z1T-)BG&;3,ZV%IU-]SQ['I2$8KT36/"-KJ6Z2#;;3DYW*ORL?<
M#^8KBM3T2ZTB0+=Q_(?NR+]TUO&I%GDUL+4IO78H44459S`.M=%X9A3R9I<#
M>6VY]L9_K7.CK78^&-,F6T)G1HED?<N\8)&!SBHJ-)'7A(-U$70"S849/H*M
MPV!)!F./]FKL5ND(&Q0#W..34E<[EV/8A3MN-1%1<*`!3J**DU"BBB@`HHHH
M`****`)K8D2X[$5:JI;_`.M'T-6Z`"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;
MU`%&[@C,N60$D<G)J'[/%_SS'YG_`!HHI`'V>+_GF/S/^-(;6%NL8X_VC_C1
M10`GV.#_`)YC_OH_XT?8X/\`GF/^^C_C110`?8X/^>8_[Z/^-'V.#_GF/^^C
M_C110`?8X/\`GF/^^C_C1]C@_P">8_[Z/^-%%`!]C@_YYC_OH_XT?8X/^>8_
M[Z/^-%%`!]C@_P">0_[Z/^-,DTZVE4K)"K`]BQ_QHHHNP:ON5_\`A'M._P"?
M4?\`?Q_\:/\`A'M._P"?4?\`?Q_\:**+L7*NP?\`"/:=_P`^H_[^/_C1_P`(
M]IW_`#ZC_OX_^-%%%V+E78/^$>T[_GU'_?Q_\:/^$>T[_GU'_?Q_\:**+L.5
M=@_X1[3O^?4?]_'_`,:='X=TUG`-J,'_`*:/_C11338<J[%G_A%=+_Y]?_(K
M_P"-'_"*Z7_SZ_\`D5_\:**=V'*NP?\`"*Z7_P`^O_D5_P#&C_A%=+_Y]?\`
MR*_^-%%%V'*NP?\`"*Z7_P`^O_D5_P#&H1X)T4=+/_R-)_\`%444KL3IP>Z#
M_A"M&_Y\_P#R,_\`\51_PA6C?\^?_D:3_P"*HHH4GW%[&G_*ON*.H_##PSJQ
M0ZAIOFF/.W_295QGKT8>E4_^%,>#O^@/_P"3D_\`\7115>TFMF2\-1;NX+[D
M/C^#OA")U=-'&5Z9NYB/R+U>C^'/AV)U:/3\,A!4_:)>,?\``J**/:3?4%AJ
M*V@ON1N?V=;_`///_P`>/^-']G6__//_`,>/^-%%2;!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>
M/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`%/4?#&G:M$([^!Y(QSL$[J#]0&&?QK
M._X5MX<_Z!W_`),R_P#Q5%%--K8SE2IRWB@_X5MX<_Z!W_DS+_\`%58L_`^B
M:>6-I9>67QN_?R'./JU%%/FEW!4::=U%?<6O^$9TW_GV_P#(K_XTJ^'-.3.V
MWQG_`*:-_C112NR^5=AW_"/Z>1_Q[_\`D1O\:K?\(;H__/H?^_TG_P`5111=
MB<4]T)_PAFC_`//H?^_S_P#Q5'_"&:/_`,^A_P"_S_\`Q5%%',^Y/)'L'_"&
M:/\`\^A_[_/_`/%4?\(9H_\`SZ'_`+_/_P#%444<S[AR1[!_PANC_P#/H?\`
MO\__`,52CP=I`.1:$$?]-Y/_`(JBBB[*4(]B['HUG$@1(CM7IF1C_,T[^RK7
M_GE_X^W^-%%(H/[*M?\`GE_X^?\`&F2Z+931LDL"NC#!!)(/ZT44`9)^'?AX
MG/\`9_Y7$O\`\51_PKKP]_T#S_X$R_\`Q5%%5S2[F7L*7\J^XEM?`>A6<PE@
ML%$B]"TKMC\V-:7]C6?_`#Q_\?;_`!HHI-M[E1IPCLK!_8UG_P`\?_'V_P`:
M/[&L_P#GC_X^W^-%%(L/[&L_^>/_`(^W^-']C6?_`#Q_\?;_`!HHH`/[&L_^
M>/\`X^W^-']C6?\`SQ_\?;_&BB@`_L:S_P">/_C[?XT?V-9_\\?_`!]O\:**
M`#^QK/\`YX_^/M_C1_8UG_SQ_P#'V_QHHH`5=)M$.5BP?]]O\:?_`&=;_P#/
M/_QX_P"-%%`!_9UO_P`\_P#QX_XT?V=;_P#//_QX_P"-%%`"QV$$3AT3##H=
(QJQ110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g911284g80l95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g911284g80l95.jpg
M_]C_X03Q17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``"OR````G$``*_(```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHP-"`Q-#HQ,CHR,0```Z`!
M``,````!``$``*`"``0````!```"RZ`#``0````!````0@`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```.[`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`#P"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]-L)WG7_`%A1+MH+G.AH
M$DDP``I6#WG_`%[(=H:ZI[;!^C+2'R8]I'N]R2D#^J83)_33`)D!Q;I_+`0?
MMUE]>ZJT;#^<SC_.4/LG36S%K>#HY[3^+BBU,:U@%<%GB'-(_*G:,?KZT/[J
M`FXF2]Q\]Q_O4=]G[SOO*LEK3S'WC^]1-;?$#XEO]Z5HX2A;;:W5MCA_:*-5
ME7E[6D[@2!/!U^"AL`/YOQW-_P#))4.<^YC=CF^X>YVT#0_UTD`D$;M_:_Q(
M^:))\2E!_P!82@_ZD)K,J3XE*3XE*#_J0E!_U(24PEW<E"N)-<$GD<$A%-AF
M&L<X_(#_`#G%`O.YA;;6/3)&N\#7MJB@D4U+W`$;':Z[B"?QU0][_P!]W^<?
M[T8X]#OH6[/)Y:1_G,<AOH>W\YCAXM>W^):C882);U]C`N<1!<XCP)/]Z&:6
MD@[K!!!(:]T'RC<C,J<\P2UH\2YO_DD=N+1^?:#\'-'\4;I7`9=/M9XV739>
M<:K<QX:7;"($:<.!\U=&X#4D_-4\;'PJ\HV5.#\@MB-X)#=)BL*[!_UA--=&
M6/%7JK?IV?_9_^T-'E!H;W1O<VAO<"`S+C``.$))300E```````0````````
M`````````````#A"24T$.@`````!%P```!`````!```````+<')I;G1/=71P
M=70````%`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L
M<FT````/<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4
M````&@!<`%P`4P!.`$<`1@!"`%4`+0!-`%<`4P`M`$8`4``Q`#``7`!B`',`
M:0!?`'``<@`S```````/<')I;G10<F]O9E-E='5P3V)J8P````P`4`!R`&\`
M;P!F`"``4P!E`'0`=0!P```````*<')O;V93971U<`````$`````0FQT;F5N
M=6T````,8G5I;'1I;E!R;V]F````"7!R;V]F0TU92P`X0DE-!#L``````BT`
M```0`````0``````$G!R:6YT3W5T<'5T3W!T:6]N<P```!<`````0W!T;F)O
M;VP``````$-L8G)B;V]L``````!29W--8F]O;```````0W)N0V)O;VP`````
M`$-N=$-B;V]L``````!,8FQS8F]O;```````3F=T=F)O;VP``````$5M;$1B
M;V]L``````!);G1R8F]O;```````0F-K9T]B:F,````!````````4D="0P``
M``,`````4F0@(&1O=6)`;^````````````!'<FX@9&]U8D!OX```````````
M`$)L("!D;W5B0&_@````````````0G)D5%5N=$8C4FQT````````````````
M0FQD(%5N=$8C4FQT````````````````4G-L=%5N=$8C4'AL0%(`````````
M```*=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M`````%!G4',`````4&=0
M0P````!,969T56YT1B-2;'0```````````````!4;W`@56YT1B-2;'0`````
M``````````!38VP@56YT1B-0<F-`60```````````!!C<F]P5VAE;E!R:6YT
M:6YG8F]O;``````.8W)O<%)E8W1";W1T;VUL;VYG``````````QC<F]P4F5C
M=$QE9G1L;VYG``````````UC<F]P4F5C=%)I9VAT;&]N9P`````````+8W)O
M<%)E8W14;W!L;VYG```````X0DE-`^T``````!``2`````$``@!(`````0`"
M.$))300F```````.`````````````#^````X0DE-!`T```````0```!X.$))
M3009```````$````'CA"24T#\P``````"0```````````0`X0DE-)Q``````
M``H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F
M9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T````&
M```````!.$))30/X``````!P``#_____________________________`^@`
M````_____________________________P/H`````/__________________
M__________\#Z`````#_____________________________`^@``#A"24T$
M`````````@`!.$))300"```````$`````#A"24T$,````````@$!.$))300M
M```````&``$````".$))300(```````0`````0```D````)``````#A"24T$
M'@``````!``````X0DE-!!H``````TD````&``````````````!"```"RP``
M``H`50!N`'0`:0!T`&P`90!D`"T`,0````$`````````````````````````
M`0`````````````"RP```$(``````````````````````0``````````````
M```````````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```$(`````4F=H=&QO;F<```++````!G-L:6-E<U9L
M3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`
M````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC
M94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC
M951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``!"`````%)G:'1L;VYG```"RP````-U<FQ415A4`````0```````&YU;&Q4
M15A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!
M```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!
M```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F
M875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D
M969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP
M90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L
M;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E
M=&QO;F<``````#A"24T$*```````#`````(_\````````#A"24T$%```````
M!`````(X0DE-!`P``````]<````!````H`````\```'@```<(````[L`&``!
M_]C_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)
M"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,
M#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(``\`H`,!(@`"
M$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!
M``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS
M`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1
M`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/3;"=YU_P!842[:"YSH
M:!)),``*5@]Y_P!>R':&NJ>VP?HRTA\F/:1[O<DI`_JF$R?TTP"9`<6Z?RP$
M'[=9?7NJM&P_G,X_SE#[)TULQ:W@Z.>T_BXHM3&M8!7!9XAS2/RIVC'Z^M#^
MZ@)N)DO<?/<?[U'?9^\[[RK):T\Q]X_O436WQ`^);_>E:.$H6VVMU;8X?VBC
M595Y>UI.X$@3P=?@H;`#^;\=S?\`R25#G/N8W8YON'N=M`T/]=)`)!&[?VO\
M2/FB2?$I0?\`6$H/^I":S*D^)2D^)2@_ZD)0?]2$E,)=W)0KB37!)Y'!(138
M9AK'./R`_P`YQ0+SN86VUCTR1KO`U[:HH)%-2]P!&QVNNX@G\=4/>_\`?=_G
M'^]&./0[Z%NSR>6D?YS'(;Z'M_.8X>+7M_B6HV&$B6]?8P+G$07.(\"3_>AF
MEI(.ZP002&O=!\HW(S*G/,$M:/$N;_Y)';BT?GV@_!S1_%&Z5P&73[6>-ETV
M7G&JW,>&EVPB!&G#@?-71N`U)/S5/&Q\*O*-E3@_(+8C>"0W28K"NP?]8337
M1ECQ5ZJWZ=G_V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P`"``0P!3`#8````!`#A"24T$!@``````!P`(``$``0$`_^$-UFAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+"`R,#$R+S`R+S`V+3$T.C4V.C(W
M("`@("`@("`B/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@>&UP
M.D-R96%T941A=&4](C(P,34M,#,M,#14,30Z,3(Z,C$K,#@Z,#`B('AM<#I-
M971A9&%T841A=&4](C(P,34M,#,M,#14,30Z,3(Z,C$K,#@Z,#`B('AM<#I-
M;V1I9GE$871E/2(R,#$U+3`S+3`T5#$T.C$R.C(Q*S`X.C`P(B!X;7!-33I)
M;G-T86YC94E$/2)X;7`N:6ED.C,Y,D(X.#5!,S5#,D4T,3$Y,#=&0S!&044Y
M-S$P1C="(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C,X,D(X.#5!,S5#
M,D4T,3$Y,#=&0S!&044Y-S$P1C="(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240](GAM<"YD:60Z,S@R0C@X-4$S-4,R130Q,3DP-T9#,$9!13DW,3!&-T(B
M(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D93TB
M,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(CX@
M/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO
M;CTB8W)E871E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HS.#)".#@U
M03,U0S)%-#$Q.3`W1D,P1D%%.3<Q,$8W0B(@<W1%=G0Z=VAE;CTB,C`Q-2TP
M,RTP-%0Q-#HQ,CHR,2LP.#HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB+SX@/')D9CIL:2!S=$5V=#IA
M8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C,Y,D(X
M.#5!,S5#,D4T,3$Y,#=&0S!&044Y-S$P1C="(B!S=$5V=#IW:&5N/2(R,#$U
M+3`S+3`T5#$T.C$R.C(Q*S`X.C`P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB
M+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!
M9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!
M`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__``!$(`$("RP,!$0`"$0$#$0'_W0`$`%K_Q`#<``$``00#
M`0$`````````````!0,$!@<!`@@*"0$!``(#`0$!``````````````0%`0(#
M!@<($``!`P("`P<)%04$"`8#```!``(#!`41!B$Q$D%189&2$P=QT2(RTQ14
M%96!H;%28H*R,U.3-'24-=46-E:6%PA"(T/457(E176BPM)C<[,D-^&#M7:&
MUE>7&!$``@$"`@4&"0@(!`8#``````$"`P01!2$Q49$206&AT3(&<8&QP4*2
M$Q05(M(S4Y,T5%7A4F)R0W,U!_#Q@A:RPB.STY2#1'3_V@`,`P$``A$#$0`_
M`/OINDLD%NK9H7F.6.FE?&\`$M<UI(<`X%I(.^$!K7Q]>/#Y>1!W)`/'UX\/
MEY$'<D`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]
M>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D
M`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D`%^O)T"OE)W@R#N2`B;YFN
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MFO:2"8J^VVM[=&XUU/1T[F`^:M96E"7HX>`Z4L\S.D\?;*:V2BO-@9O;_P!2
MN8SLMN\54TZ-J>UOHG-X3WO4TN('`'*/*P?H5=_Z"UH]YD]%S:8<\'YGUF<V
M_ISI[B6M9FZ:CE=A^ZN-+3TAQ/[/..IGPGE*-*VKQTN&*YBVHYUEM;0KCA>R
M2:Z=729C!G7,-4P24M^=4QD8A]/WA.W#?QB@<%Q::T-8,LXRC47%3DI1YFGY
M"I];\SC7>*CWFD_EE@R/KAF;^L5'O5'_`"R`?7#,W]8J/>J/^60#ZX9F_K%1
M[U1_RR`?7#,W]8J/>J/^60#ZX9F_K%1[U1_RR`?7#,W]8J/>J/\`ED`^N&9O
MZQ4>]4?\L@,EMN8[Y-2,DEN4SWESP7&.G!P#R!VL(&@("^\?7CP^7D0=R0#Q
M]>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<
MD`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]>/#Y>
M1!W)`/'UX\/EY$'<D!;SYGNM/AM5T[B['`!D`U;I)BWT!'.S??CH96N8/^%`
MX\9A&E`4/K3F'^JS^]4O\N@'UIS#_59_>J3^70#ZTYA_JL_O5)_+H!]:<P_U
M6?WJD_ET`^M.8?ZK/[U2?RZ`Y;FG,)<T&ZSX$C^%2[_Q=#*UH\L7/IBZ3X+E
M<88\YW&.&&OK8HF"CLN#(XZJ5D;`76MQ(:QH&DXJXA;T7"+]FL<%MZSY[7S;
M,HW-Q"-Y)0C-X:(ZL7S%K%TQ=*\S@V'.%VF<=R.@LS_8VDK+M[=:Z<5OZS2.
M:YK-X0O)M\T8O_E+:OS+TY7K&2DZ5,XY;D?VKX*?)\M,P_$JS+51(6C>V\5M
M!V=/1*VA-<_%Y4SA7I=XKSY5'.[JWD^5>R:]65-OI,2K+C^I:T05%QK?U&YA
MN=!3#G):>@RQDV@K&0X@%[I:C+TT;RTG3L`'=7=5,NFXQAEL8R>V4FO*5=6Q
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MI>^_ET^0V'Z(6/=+;ZE=/6/C^<_F$]T/FD/<NEWICN`)@Z5\VVF7#L74%)E-
M\0/#3U>6YP[A[);PM[6.NVA)<_%YF1;C-,[KKY&>7%*6V*I8;I4WY3`+ETE?
MJHAVGV?IZN-<T:H;C8,IT4YW@)H<N2PD]4!2H4LK?TE@EX')^<HKB\[]1Q=I
MWLE-;)4Z47O5-HP"Y]/?ZQ;3M&JZ0,T2Q-QQGH+/DZOAP&[M4^7'/`PWVA28
M6>2SU48)\[DO.4=SWA_N/:XNIF5=QVQA1DNBGCT&'O\`U<_J6B>8Y>EN_P`4
MC3@Z.6RY2B>#JP+),M-<#BI'PG+7JM([Y?.*I]_>^46XRSZLI;'"DO+3'_\`
M77ZE?_R[??(^4/\`ZVGPG+?PD=\NLQ_OWOE^?U?4I?\`C!_5W^I4`D]+M]P`
MQ/\`<^4-0_\`C:?"<M_"1WRZQ_O[OE^?U?4I?^,]%9*OGZVLXVVW7J7IF^K5
MGNE-#6T=1<Z#*M97344[0^&=MNH<LDQ\[&0YHDD:<#I`53<SR.WE.FK)SJ1>
M#P<DL5KTN1]`R>T_NCF]O;WDN\D;>TJQ4HN:I2DXO4^"-/1BM*Q9Z"R]2=+U
M#S<N:/U#=(.8YVX%]/;K-D:P6\G''9#FY8JJQ[>JX'!5=6YMI-JCEU*$>=RD
M_P#BP/>6&1YS1X99EWQO;B>R$*%*/_;E+I-KQ9YSC%&R,9CN$H8T-$D\5MDF
M?A^U*]MOC:]YW2&M'`H3C%MOA1ZB$JD(QC[63P6MX-^-X+%^(G;7G7-<T<QF
MO=3(6R-#2Z"A&`V<<!LT@W5RFDG@D2:,I2C)R>+Q)49OS,TX^-I3P.@HRWB%
M."M#L7D>=[X-$U2]W#&V!A/F&`A`25-FZXU+MAE?4-?@3LOB@U#7@YL9:<!U
M$!>^/KQX?+R(.Y(!X^O'A\O(@[D@'CZ\>'R\B#N2`__0^^6]?--Q^*3>P*`U
M$@"`(`@"`(`@"`(`@"`Y`)(`&).H(##;OG[*MEEDIZFY"IJHB1)2V^,UDC'#
M06/?&1`QX.X7KO"VK5%BH8+GT%9<YQE]K)PG7XJBY(KB_1TF`W#IE:-IMHL1
M=Z6>YU.R.`][TH)PX"]28V'Z]3<5%7O,M*M[3QR?F768+<>DC.5R#F^-&VZ)
MVCFK73QTN`WN?(?.3PXJ1&UH0U1Q?/I*JMG>9U\5[QP1?)!8=.LUOF"HJ*NE
M=)65-15R&6,F2KGDJ'%Q)TXRN=@>HI"2BL(I)<Q5SG.H^*I.4I<[;\IAZ&H0
M!`$`0!`$`0!`$`0!`$`0%:FJJJB>):*JJ:*0:0^DGEIW8\/-N:#YJPTI:))/
MPF].=2D^*E4E&7,VO(9M;NDO.-OV6NN,=RB;@.:N=/'.<-X3L$<PXRH\K2A+
MT<'S%I1SS,Z."==3CLDL>G69S;^F2%VRV[6.2,Z-J:VU#9&<)YBIV7^8'J/*
MQ?H5-Y:T>\T7@KBT:>V+\SZS/[/GG*][ECIZ2YLBJY2!'25S'4<TCC^Q&9?W
M4C\=P..*C3MZT$W*&CFTEQ;9M874HPIUTJCU*7R7XL='29<002"""-!!T$'>
M(7$L3A`$`0!`9=:?@,?]J3_F.0$D@"`(`@"`(`@"`(`@"`(")N7;Q?V7>B$!
M&H`@"`(`@*9E8-W'@&G_`,$!T$_9#9;NC7U=Y`M#Q-`SV*U,KZV=U(V:66MJ
MY7.G<Z4;3ZB1YV6'!H&)T:%9JI/ABN+1@CQT[*V5Q7DZ6,N-O3IUMEXQC(QL
MQ,9$WTL;&L;Q-`"U\)WC&,%A"*2YM!V63)!YF^SE[^(2>S8MZ7TM+PD+,ON-
MW_+?E1Y_&H=0>@K4\(<H`@"`(`@"`(`@"`(`"0<02#OC0>-#/@+&NM5JNC#'
M<[9;[@T@C_JZ2&9VG>E+>='F.68RG#3";3YF<*]M;7*X;FVIU%^U%/IUFOKE
MT0Y,KMIU+!76:5VD.M]4Y\`=O][57.LV>`$*5"^N(ZY*2YUU%'<=U<HKXNG"
M=&7[+T;I8FOKKT(W2)DKK1>J.N;LNV(:Z&2BF.@X#G8^>@Q\P*5#,8-KVE-K
MP:2AN>YUS%2=I>0FL-4EPO>L5Y#]+\@T%5;\AY,HJF+9J*3*]DIYPPB1@EBH
M(6/#7MQ#FAPT'=7D+J:G=7,HZG-^4_1>14*MODN4TJJ^7&VIIX:=*BDS*EP+
M4(#(+-[5/_Q&^P7&IVB5;]F7A\Q,K0[A`2-K^%M_L/\`00&3H`@"`__1^^6]
M?--Q^*3>P*`U$@"`(`@"`(`@"`(`@._-O#=LL?L>FV7;/*PP0S@\,<'@8QG&
M:6#*68YH)'PS1VF<QRQ.+)(RYT<;BQ[<"UQ8\C$;ZZT$G7I)K1Q$#,Y2CEU[
M*,L)*F]*\1X_C`#&@:!L@^:1B2=\DJ[/G"6"P6H[H`@*,\+*B,Q2C%CM8W01
MI:X'<+2@(&:R2@DP2M>-QLG8NY0Q:?.0$=+0UD/;P/PT]DP;;<!CNMQWD!:'
M02#H(UC=0!`$`0!`$`0!`$`0!`$`0!`$!P0",#P'>((U$$:0X'41I"!I/6>P
M\J3SU65\OU%3*^>>:U4KI9I';4DC@TMVGN.ESMEHTZRJ.JDJM1)8+B9])RZ<
MJF7V4YR;FZ:Q;ULGUS)@UZ`"3O`$GB&E`7<5!638%E.\-)'9R?NVX;^+\#AY
MB`DH;)(2#/*UH_:9'V3NIMG!HQZA0$_%$R&-L48V6,&`'HDG=)*`J(`@"`(`
M@"`(`@"`(`@"`B;EV\7]EWHA`1J`(`@"`L7N+B<3C@3AP:=Q`=4!R-8ZH]%`
M:?J_A53\9J/^<]6"U+P+R'F*GT]?]Y^4MUL:A`0>9OLY>_B$GLV+>E]+2\)"
MS+[C=_RWY4>?QJ'4'H*U/"'*`(`@"`(`@"`(`@"`(`@"`X(Q!&_H0&Z,O=+$
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M#`+0[E[%;*N328Q$-&F1V!P(.G9&T4!+4=N[VDYUTFV\`@!HP:,>$DD^<@)-
M`$`0'__2^^6]?--Q^*3>P*`U$@"`(`@"`(`@->YLZ6>C;(TTE+FC-]LM]QC:
MUS[1`)KC=V[;0Y@DH:*.5\+I&G$"0M.'`I%*TN:ZXJ5%N.W4M[*7,>\>193*
M5/,,SIPK+7!8RGZL<</'@:"S#^L7*-+MQ94RE?KZ\8AE9=YH+%1$[CA`.^ZY
M[-WM6E6%/)JKP=6M&/,M+\R/'WG]S<MIMQR_+:U9_K3:IQW:9=!H[,'ZJNE2
M\<XRUR67*L#\0UMJH!5U;`<1HK[D9W;7"UC5.IY59P[2E-\[T;D>3O?[A=X;
MGB5O*E;P_8CC+UI8Z?$C5C>E?I097>,F](.;>_=K;YTW>H<S'>-,3WJ6>IV,
M%*]TM>'A]WAP^`\\N\.?JM[?XS<^UV\;PW:O%@9K6_JGZ4;=E:^4MW=9,T4[
M[9)&\W*@%%6D<Y%B[OVVNAVGZ-;HW+E#*K25:FX*4)8\CQ6YEQ+^X&?T[*YI
M73I7%-PP^5'AER>E'#I1A%A_53E6I$<>9,M7NR/(#75-MD@O-&-`[(QCO:L:
MWUI4JIE558^SJQEX=!7VO?RPJ8*]LJM)[8X37F9NS+/25D/.4C8,MYGM]?6/
M8YXMLG.T5SV8QC(10U<<4K^;&EVQM8#3J4*K:W%'34I-+;K6\]/99WE.8M1L
M[Z$ZGZNJ7JLSA1RS"`(!CAJ0%&6"";VV*-^YBYHQX\,4!'RV>EDQV-N$G=8=
MH#UKL?10%A+9)Q[3+'(-.AX,;MW#3V3<4!'2T-7#CMP28>F:-II&_BW'1U4!
M:ZC@=!WMU`$`0!`$`0!`$`0!``"3@`2=X:3Q!`7<=!62]K3O`(Q#GX,;AACC
MBXC`(#V9D>R3.RCEHS31Q_W32Z(P9#AV6C$[+525UA6JIZ^(^CY7_3;'^6C-
M8K/21]N'S'##LW8#DLV5R)Q(1P0Q#".*-G"UC0>/#$H"J@"`(`@"`(`@"`(`
M@"`(`@"`("RJZ9TY:6.:"T$8.T`XG?W$!&/I:AG;1.(&ZW!XT88]KB=U`6Y!
M&L$=5`$`0%@=9ZI]%`<(#D:QU1Z*`T_5_"JGXS4?\YZL%J7@7D/,5/IZ_P"\
M_*6^YCN#6=P=4K)KS\A%U=\LU!B*NYTD3AKC;()I?,CAYQV*WC3G+LP9&JWM
MG0Q]K<P3V8XO<L3!<PYUMU;;JRVVZ"IG-9%S#ZF=G,0QQES7.>QA)DD>0W`:
M`%)I6\E.,YO!+24E_G%O6H5:%O"4G)88O0EX.5ZC60T:%-/-A`$`0!`$`0!`
M$`0!`$`0!`$`0&I^F9K79.8UP#FF\T&(<`0>PJ=8.@J98?>/]+/,=[M.413U
M>VCY&>:;7<[K8IVU-CNMSLU0UP<V6UU]50N!!QU4\K&'S0K><(55PU(1DN=)
MGSRVN;FRFJEE<U*,URPDX^1H_53]%F:LR9VR?G:JS?>:S,53:<S6NAMU1<S'
M--34<UH?/)!MMC890^8;1+]IV.ZO'9[0HV]Q15"FHIP;>&W$_17]K,WS/-\L
MS2>9WLZ\Z=>,8N6EI.&.&/+IVGM-H#1@T!HWF@`>=@J,^HG*`(`@"`(#_]/[
MY;U\TW'XI-[`H#42`(`@"`(`@`0+6C\ENGAK1TR](Q#0"[,&D@#$_P!W4&LZ
MRO76/W*V_=\Y^<>]J7^Y\[?+[;_EB:F4D\\$!P2!K('5T(8QPUEA>K;<;E8;
MQ#;J"LKII*&1K(Z6GDF+G%\>#06MV03PD+>G.$*M-SDDL3%2A7N+>O&A0G.7
M#R)LUY:NAS/=Q#'3T=%983A^\NM6WG<,,3_TM+S\F(X2%*G?V\<<&Y/F7G9!
MM^ZV;U\'.G"E';-Z=RQ9Z"Z'>A6CL>?<M7>XWZ:X5M'45+XZ>BHV4M("^AJ8
MW-=-,Z2H>W!QU`:577N82G0JPA3PBURO%Z]Q[+NUW3I6N;65Q7O93J1D\%%)
M+3%K6\6>[FV2V-`;WN78;KY)"3U3M!47M:GZQ]95A:+^%CX6SI)8;<\=BR2(
M[\<KO0?M`HJTUK>)K++[66J+B^9]9&39:D&)IJMKAN,GC+3RV$CSENJZY8D6
M>5R_A5D_#UHBIK1<8,2ZE<]HT[<)$K<.$-[(<2Z*I!^EI(D[.YIZZ3:YM)'.
M!8[9>',=Z5S2T\1`6^O417HUZ`@"`X0%&2F@E!$D,;\=]HQY6L("PEL]))CL
M<Y"[<V7;31ZUV/HH"/ELE0T_NI8I1O.QC=P:3B,4!'R457%I?!(`-;FC;:,/
M5-Q"`M<,-!T%`$`UG`:3O;J`NXZ"KE[2!^&^\!C>#2XC%`2$=CF)!EFCC&\P
M%[CIU8G9`0$A%9Z2/`O#YCZMQ:WDLP]%`7\<$,0`CBC8!JV6@'CPQ*`JNU'J
M'T$!Z\R7]D,M?Y13?ZRI;G[Q6_>/H^5_TRQ_EHR9<2<$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`='1L>,'L:[J@%`6SZ&!VH%A]2='$<0@+5]N</:Y`X:=#@6G
M@U8C!`0CX)6N(+"=)U$'=.\@.C8I':F.ZI&`XS@@*\=*]SFAQ#<7`;YUC>T(
M96EI'CG,&>;RVZW2EI(Z2DCI[C7P-D$;IYGB*KEC#RZ4[#2[9QPP."OJ5M!P
MA*3;;2\A\MO<ZNU<W,*4802J26UZ&URF$5=WNE>3WY<*N<']ATSFQC@$4>PP
M#S%)C3A'5%%/5NKFM]+7D_'HW+01P`&H#BT\:W(YR@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`U1TR?8]G^<T'L*E3+#[Q_I9YGO=_28_SH>1GEM71\U/U"_0)]B.
MD?\`]X6?_P!"D7D>\?WFW_<?E/O_`/9O^E9W_P#JA_VV>\UYT^Q!`$`0!`$!
M_]3[Y;U\TW'XI-[`H#42`(`@"`(`@"`\'=,WZ=ND"_9VS-G++C[+>:"_5HN+
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MS<-LK&1B.)HIW!K(VMC;K;@`Q@:/.7-:9)\Y,J\,*$XQ22PU+08I0V.\W/#O
M"UUU2T_Q&0/;%YLL@9&!YJ[2J0AVI(@TK2ZK_0V\Y>+1O>@V7E#(M\MUXH;O
M<>]*6&D,C^]A-S]5(Y\+X@TB(&*,`OQ)+CJ46M7IS@X1Q;9>9;E5U0N:=Q6X
M8QCCHQQ;T8<F@W(HAZ0(`@"P"G)%%,-F6*.0;TC&N]$$K*;6IF)0A-83@FN=
M$7-8K;-CLQ/IW''LH)"T`G=V';35T56:>EXD2IE]K/2HN+YGYB*FRU*,33U3
M'C3@V=A8X[PVF;3?.6ZKKTH[B)/*Y+Z.LGX5ATD5-:;C!I?3.>-UT)$K?]`E
MWG+HJD'JD0YV=S33;I-KFTD>[%IP>"P[SP6GB=@MR,]#P:P80!`$!1DIX)?;
M(8W\+FC'C&!0%#Q=0X@][1Z-0[/#<]5P("O'!#%[7%&S#5LM`/'K0R5D,!`$
M`0'!U'J'T$!Z\R7]D,M?Y13?ZRI;G[Q6_>/H^5_TRQ_EHR9<2<$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`0+^W=_:=Z)0'5`<@D$$:P01U1I0:CS+G3H7
MO+[G6W7+$\%QI:^HFK)+=5S-I:ZDFJ)'2S1PS/P@JX#(XEF):]H.!Q5M;W]-
M0C"LFFEACK3ZCP6:]U;IUZMQE\E.G-N7"WA)-Z7@]36.K4T::NN6,R60D7:Q
M72B:-<LE)(^#JBHA$L)'KE/A6I5.Q4BWX3R]QE]_:-JYLZD%MP>&]8H@6O8[
MM7-)W@1B.J-8*ZD--/4SL@"`(`@"`(`@"`(`@"`(`@"`-[-P8P&1Y.`9&"]Y
M.\&L!.*>%A?*>$=+YC(*/*N8JX;4%IJ@PZ0^<-IFGJ<^YCCQ+C*XHPT.HL2?
M1RR_KZ86LL-KT>7`XK,JYBH6[=1::HLW7P-;4M'5YASRWS0L1N*,W@JBQ%;+
M+^@FYVLL-JT^3$TITL6^XW++,5#;;;<;E7/O=O:RBH*&JK*MQV:D8"GIXI)?
M.5C93A&LY2FE'A>EM(\=WIHUZ^6PHT*$YUO;Q^3&+E+4^1)LQ;*?Z5NG3-IA
M?%DN7+M%-LGQCFZJALD,<;L/WII'F6YR-:#CLMAQ*D5LXR^CBG7XI;(K'IU%
M/EW]O.]V9<#CE;H4GZ5:2II<^&F3]4_4+H&Z%J#H0R?46"*[R7Z]7JO9=\QW
M81.I:*6OCIA2P4MKHW%TD%!108M:YY,DKB7.PT`>2S&_EF%=5'#AIQ6$5RX;
M6]K/T!W/[JT>Z>63LXW+K7=6?'5GAA%RPP2A'DC%:%CI>MF[5`/5A`$`0!`$
M!__5^^6]?--Q^*3>P*`U$@"`(#ASFM&+G!HX2`@+=U7"W42X^I!XL3@$!;NK
MG?LQ@;VT2?.&"`MW5$SM;R.!O8^AI0%$DG222=\DD\9TH!B0",=!UM.EIX"T
MX@A!S<ACURRGEB[XFX6*WRO=KFBA%+4=42TW-.QZN*ZPK58=FH_*0J^76%SC
M[:T@WM2X7O6!B@Z)LH<_SI%V,6./>IKSS7]GG.;YXM]<NOOE?##1CX"O_P!N
M9;Q8XU>'9Q>?#$FJC*F6;1:+B;=8[?!(VD?A.^$5-1B"S3SU3SKL=&Y@M(UJ
MTZD>.JVL25/+[&VMJOL+2">&O#%[WB8%B2`"=`U#4!U`-`4LJ<7@CA`$`0!`
M$`0!`$`6`4Y(H9ALS112C>D8U_GD8K*;6ILQ*,)IJ<%)<Z(J:PVV4DMC?3N.
M[#(0T?\`EOVFKHJLURXD.>7VT]*BXOF?F(N;+<HQ-/4LDWFS,,9/!M,VF^<M
MU77I1(D\KDL73JIK8T14UJN$&)?3/<T:WPX2M\W9[(>:%T52#]+21*EI<T\6
MZ3:YM/D(_?!Q!&@@@@@[Q!T@K<C;5RA`$`0!``"=0)ZB&0A@X.H]0^@@/7F2
M_LAEK_**;_65+<_>*W[Q]'RO^F6/\M&3+B3@@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@.0USC@T%QWF@D\0TH->HL+G=;39873WFZVVTPM:7%]QK:>DT`8D[$
MLC9#HX%M"$ZCPIP<GS(XU[BVM8N=U<4Z</VI)?I->5F?<MPXOIZJ2X;?9QFB
MA<^*1KQM,<V>3FX]ES3B"NBMZKUK#PD*IF]C%)PJ.>*T<*T;V8Q4])4Y)%%:
M86MW'U=0][B.%D(8T<9756J]*;($\]G_``K9)<[Q\A;,Z2;H'`R6RWO;NACZ
MF-WF$O<%M[M#]9G..>7"[5"#7C)ZCZ1K7+@*ZDJZ)QUOC#:J('UA9*!ZTKG*
MVFNS),FTL[MY?2TY0>]=9EU#F&RW`;%'=:20O`Q@DE$+R2.U=!.&$G@P*XRI
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MF\+JSJ0YW%X;UBB$:]C^U<UV_@0<.KAJ70BIIZF=D`0!`$`0!`-;@T!SGN[5
MC&N>\]1K07%8&MI+2R?H<K9BN(:ZFM-4V-W\6I`I(AP[4Y82#P!<I7%&#PE4
M6.\GT<LO[CZ.VDH[7\E=)EU%T8W"3`W"XTU*-&,=,Q]3)PC;=S<0/*"C2OH+
ML0;99T>[M9X.O<1BMD5B]^A&6T'1WER`MYZ&LNDHPQ;/,[F]K_@4P8T@'<*C
MSO*\M":CX"THY#80PXH3JRYWHW(S^W99-,UK:"T4UO81H<(8J<X<+R#*3BHL
MZKEIG-MEW0RYTTE0M8PCX$OTF019=D=IJ*H#'6(FESNIMOP'G+DYKD1.C8-_
M25=WZ24ALENA()B=,\:G3/<[_1:6M6..6G22(6="&GA;?.3-(XTCR^D#:1Y;
M@9*9C(9"-&@R1M:]PZI*TUZV2HI0>,(I/F23WZR49<ZH'LW-ETXDR#LCHW7`
M@E`7D=TC.`DC<WA:0X8]30<$!>1U=-)VLS`?2N.P[S`[#%`7'"-(WP<1QC0@
M"`(`@"`__];[Y;U\TW'XI-[`H#4.(WQQA`,1OCC"`8C?'&$!!2R[;W%T@)Q(
M&+AH`T`#<&A`4]MGIF\H==`-MGIF\H==`-MGIF\H==`-MGIF\H==`-MGIF\H
M==`-MGIF\H==`-MGIF\H==`6]7%'5TM12ND#&U$+XBYI:2W:U.`)P.!`68OA
MDI+D-*D%4A*FW@FC6E7E^YTA=LPBKB&.$M*X/Q&YM1DB1APW,"ID:L)<N#*.
MI97%/'"'%':NHA7_`+H[,H,3AK;*#&[B?@5TT/4R,TUVDT^<Z<['[HSEMZZR
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M-=Z;W@CLAA'])*6/IISW2N9"VYT^8FC`<S74D=9.1J`[YI.;J`3ODE:5+&W:
MQ<>'P/`[VW>/,Z;4?;*LMDEB]ZTGJGH?O.8^E.\26.IL%/EV2&WR7*6Y2W!L
MM.:>&6**5L=`X=^F8\\"T8[.^0JB]A2LX*HJCDL<,,/.>X[N7%WG]R[1VT:,
ME#B<F\5@FD\(Z\=.CD/T!ME#!:;;06NG>Y\%OI8J6-\I;SDC8FX%[]G0'/<2
M<!J7FYR<YRF];9]>MZ,;:A1MX-N$(I+$OL1OCC"U.PQ&^.,(!B-\<80#$;XX
MP@&(WQQA`,1OCC"`8C?'&$`Q&^.,(!B-\<80#$;XXP@&(WQQA`,1OCC"`8C?
M'&$`Q&^.,(!B-\<80#$;XXP@&(WQQA`1UPO5DM$9FN]ZM%IB:W:+[E<J2C['
M?#)Y62.'4!Q6T83F\(0E)\R;.-:YM;9.5S=4Z<?VI)>5XFJ[S^H#HLM!?'!?
MGWZH;B.:L=.Z>(N&YWY4&"F`QW<2%-IY;>3TNGPKG?F//77?'(+;%0NW6GLI
MK%>L\$:GO/ZH9I`YF7LO4%*-.Q4WFX"JD&\324ABBQX#(5,IY0E]+5;\"ZSS
MEUW_`)/%65C"//.6+W1P726]DS'G_I(MLMRKND"ILMM[\GHO%V7:>GH'.,+6
M.>XU$1:X-<),!BYQ6M:-M9S5.-LI3PQQD\3IEU;.N\-M*ZK9S*E;\;CPTHJ.
MK#E7AT:R_INCC)\<G?%PAJ+_`%9TNJK[<)J]SG;YC?((AIX%RE?7#6$&H1V)
M8%A2[MY3"7'6HRKU=M23ET:C/GV.Q5$4>S3Q0AL;&-=2R\SLAC`T-`!+>QPP
MTA1U.:U/$N96-I.*2I):.308_<LM04E+4U=/7XMIHG3.BF#,2QN&($C"WLM.
MZ%TC4;:3CK(-QET:5.I5A5>$5C@^LPT30D8\['I]6WKKL5.*VCGH?=8^6WKH
M,5M.#)`[7)$>$O9B.H<<0@T,DJ._7"W$=XW>HIP-(8VJVHO>I'/9AP8+64(2
M[44SO2NKBCA[*O)+9CHW&64?23=8,&U?B^O:,,7.PII2,=)VX7;!)&^U<96T
M'V<46-+.[J."JQA-;GT&54?278IL&UL510N.M[71U4(/"8RV0#UJXRMIKLM,
MGT\\M9:*M.4'O1EM%F6PW!NQ1WJW3AV@P25,4;CB-3H*@MQXBN4J52/:@RRI
M7MI76%*Y@T^1O#H9$W;).2[[B^XY?M,DKA\*IHVT=3B?VQ/1NB+CNXZ5O"XK
MT^Q5>&S6B-<91E=WBZ]C3<GRI<+WK`UO=.@K+E1M.M%YN-K<>UBJ>:N-.W@)
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M05]14SNDEN$3*:J=`'-%/[?^^9%LZ6@`8JGNZT95<%4Q@ER=)[S(<MN(6:G.
MTX*TI-XR6#PY->G#8;-BL#G8&IK&`Z.QB[,]0O>0/.*A>T7(CT4;"3:=2KNT
M^4DHK-;(^V;SYUXS28CDMV6K7CEM)$+.WCKAQ/G)2-L$0V8FPQ`;D;6-\\:2
MM23%*/9BEX#OMM].WE#KH9&VSTS>4.N@&VSTS>4.N@.['-Q[9NK?'`@*NVST
MS>4.N@&VSTS>4.N@&VSTS>,==`2-LE_ZC8$G8EKB6[6@D#0<,<,0@,@Q&^.,
M(!B-\<80#$;XXP@&(WQQA`?_U_OV?VCNT[4]OVGKO4H"Q\GH!Y/0#R>@.AUG
MYKU[NOS>%`<>2T`\EH!Y+0#R6@'DM`/):`>2T`\EH#LW7_AOK=:PP4)^V'S-
MJ_C]MYG`MEXS2>OT?&4/P^L[S3U!^'TWCU!^'TWCU!^'TWCU!^'TWCU!^'TW
MCU!^'TWCU!^'TWCU!^'TWCU!^'TWCU!^'TWCU!^'TWCU"G+VH^S?;?Q>UU'5
MZI97+VC66K^'XRA^%%GUCG]B/PHGK#[$?A1/6'V)CU1[?+_VS]L=\(]OU_Q?
M]YOKK'4OI/$19]N?W37RZ_'SE'_]6K/VIK_Z9?47;._[=[GP+MO7+67_`,GC
M-Z>O_P"KXB;M_P`)D^RWM3OF_P"$]LWVS_=;_#@N<M7I>,DT/I']#J]'7_D3
M/D]<R8/)Z`>3T`\GH!Y/0#R>@'D]`/)Z`>3T`\GH!Y/0#R>@'D]`/)Z`>3T`
M\GH!Y/0#R>@,?O/MD?V/U#YY]LUGVO@76'+VO$0[KM+Z'_7K+,:A]@]6YJ\S
M@6?7./(ONQS^!$]<?^L2=)[2?LOV[O@GM.H:_5[ZTEKY?&2:/8_AZ_1U?YEU
MY!6N\Z^J=VZO\$];J0RO$</[1WS'J/;]IZ[@0/4]19?A9;;SE]F/PLF\?9C\
M+)O'V8_"R;Q]F/PLF\?9C\+)O'V9T/;M^R>YK[?7^RG)Z1J]?\(F!J'S7J&K
M5JW.!:$H>2T`\EH#M5?!'_-O:GX5\$W>W]2LK6*GT;\^HQG\#KMZY!^P'X'3
MUQ]@7]N^$C[+=J?F[X3K&KU*TGJ]+QG:AV_X?^G63,O;_P"'ZA[;V^KT%S1)
MEKZRGY+0P/):`>2T`\EH!Y+0#R6@'DM`/):`>2T`\EH#LW7_`(9ZW6@.WD]`
+/)Z`>3T`\GH#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
